<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPR</journal-id>
<journal-id journal-id-type="hwp">spcpr</journal-id>
<journal-id journal-id-type="nlm-ta">Eur J Cardiovasc Prev Rehabil</journal-id>
<journal-title>European Journal of Preventive Cardiology</journal-title>
<issn pub-type="ppub">2047-4873</issn>
<issn pub-type="epub">2047-4881</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/2047487312445001</article-id>
<article-id pub-id-type="publisher-id">10.1177_2047487312445001</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Vascular biology</subject>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Endothelial microparticles: missing link in endothelial dysfunction?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Yong</surname><given-names>Pearly JA</given-names></name>
<xref ref-type="aff" rid="aff1-2047487312445001">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Koh</surname><given-names>Cai Hong</given-names></name>
<xref ref-type="aff" rid="aff1-2047487312445001">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Shim</surname><given-names>Winston SN</given-names></name>
<xref ref-type="aff" rid="aff1-2047487312445001">1</xref>
<xref ref-type="aff" rid="aff2-2047487312445001">2</xref>
<xref ref-type="corresp" rid="corresp1-2047487312445001"/>
</contrib>
</contrib-group>
<aff id="aff1-2047487312445001"><label>1</label>SingHealth Research Facilities, Singapore</aff>
<aff id="aff2-2047487312445001"><label>2</label>Duke-NUS Graduate Medical School Singapore, Singapore</aff>
<author-notes>
<corresp id="corresp1-2047487312445001">Winston Shim, 9 Hospital Drive, School of Nursing, #03-02, Block C, SingHealth Research Facilities, 169612 Singapore Email: <email>winston.shim.s.n@nhcs.com.sg</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>20</volume>
<issue>3</issue>
<fpage>496</fpage>
<lpage>512</lpage>
<history>
<date date-type="received"><day>27</day><month>12</month><year>2011</year></date>
<date date-type="accepted"><day>21</day><month>3</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The European Society of Cardiology 2012 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">European Society of Cardiology</copyright-holder>
</permissions>
<abstract>
<p>Vascular homeostasis is an integral reflection of quiescent, but competent endothelium. Endothelial microparticles (EMPs) are circulating submicron-sized membranous vesicles released by endothelium that are increasingly recognized and play a multitude of biological roles reflecting competency of endothelial function and vascular biology. EMPs have been shown to act as primary and secondary messengers of vascular inflammation, thrombosis, vasomotor response, angiogenesis, and endothelial survival. These often-neglected vesicles are emerging as potentially useful indicators of dysfunctioning endothelium, whereby differential presence of EMPs is linked to disease manifestation. In this review, we outline the evolving understanding of EMPs from mere passive vesiculation to active messenger in pathophysiological responses. Current evidence implicating EMPs in cardiopulmonary, renal, cerebral, and metabolic disorders warrants vigorous clinical validation. While studies of EMPs face significant technical challenges that await standardization and consolidation, unravelling its biological significance in endothelial dysfunction could herald the advent of novel non-invasive surveillance platforms for vascular health, risk stratification, and disease prognostication.</p>
</abstract>
<kwd-group>
<kwd>Biomarker</kwd>
<kwd>disease prognostication</kwd>
<kwd>endothelial dysfunction</kwd>
<kwd>endothelial microparticles</kwd>
<kwd>risk stratification</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-2047487312445001" sec-type="intro"><title>Introduction</title>
<p>Endothelial dysfunction occurs when perturbed homeostatic endothelium disrupts vascular competency. Such disruptions result in reduced vasodilatation, heightened proinflammatory, and prothrombotic property of the vascular network.<sup><xref ref-type="bibr" rid="bibr1-2047487312445001">1</xref></sup> Nitric oxide (NO) is one of the most important vasodilating substances released by the endothelium in regulating vascular homeostasis. It counteracts the actions of potent endothelium-derived constricting factors, such as angiotensin-II and endothelin-1, inhibits inflammation, and has anti-aggregant effects on platelets. It is not surprising that reduced NO bioavailability and decreased activity of endothelial nitric oxide synthase, coupled with production of reactive oxygen species, is a well-recognized pathogenic mechanism leading to endothelial dysfunction.<sup><xref ref-type="bibr" rid="bibr2-2047487312445001">2</xref></sup> Endothelial dysfunction often precedes atheroma development and is linked to vasculopathic diseases such as acute myocardial infarction (MI), acute coronary syndromes (ACS), coronary artery disease (CAD), hypertension, diabetes mellitus (DM), stroke, and peripheral arterial disease.<sup><xref ref-type="bibr" rid="bibr3-2047487312445001">3</xref>,<xref ref-type="bibr" rid="bibr4-2047487312445001">4</xref></sup></p>
<p>Endothelial dysfunction is traditionally assessed by methods such as Doppler flow measurement of endothelium-dependent vasodilatation, venous occlusion plethysmography, cold pressor test with coronary perfusion via positron emission topography (PET), laser Doppler flowmetry, and ultrasound.<sup><xref ref-type="bibr" rid="bibr1-2047487312445001">1</xref>,<xref ref-type="bibr" rid="bibr3-2047487312445001">3</xref></sup> However, disadvantages of these methods lie in their invasive nature and poor correlation to actual endothelial function. New insights in endothelial dysfunction are emerging from studies on vascular microvesicles such as microparticles (MPs), apoptotic bodies, and exosomes.<sup><xref ref-type="bibr" rid="bibr5-2047487312445001">5</xref><xref ref-type="bibr" rid="bibr6-2047487312445001"/>–<xref ref-type="bibr" rid="bibr7-2047487312445001">7</xref></sup> MPs are 0.1−1 µm anucleated membranous vesicles that express high levels of phosphatidylserine (PS) and lipid rafts. In addition, MPs harbour RNA, low amounts of DNA, and histones.<sup><xref ref-type="bibr" rid="bibr5-2047487312445001">5</xref></sup> While apoptotic bodies similarly express PS, they are 1−4 µm in size and are rich in genomic DNA and histones.<sup><xref ref-type="bibr" rid="bibr6-2047487312445001">6</xref><xref ref-type="bibr" rid="bibr7-2047487312445001"/>–<xref ref-type="bibr" rid="bibr8-2047487312445001">8</xref></sup> In contrast, exosomes are RNA and micro-RNA-containing vesicles of 40–100 nm that express lysosome-associated membrane protein-1 and tetraspanin CD63, but low in PS-binding annexin V (AnxV).<sup><xref ref-type="bibr" rid="bibr8-2047487312445001">8</xref><xref ref-type="bibr" rid="bibr9-2047487312445001"/><xref ref-type="bibr" rid="bibr10-2047487312445001"/><xref ref-type="bibr" rid="bibr11-2047487312445001"/>–<xref ref-type="bibr" rid="bibr12-2047487312445001">12</xref></sup> While apoptotic bodies are known to form in late stages of apoptosis,<sup><xref ref-type="bibr" rid="bibr13-2047487312445001">13</xref></sup> MPs are released early during apoptosis and are produced when cell membranes undergo cytoskeletal arrangements and surface blebbing.<sup><xref ref-type="bibr" rid="bibr6-2047487312445001">6</xref>,<xref ref-type="bibr" rid="bibr12-2047487312445001">12</xref></sup> In contrast, exosomes are secreted when intracellular microvesicles fuse with the cell membrane.<sup><xref ref-type="bibr" rid="bibr9-2047487312445001">9</xref>,<xref ref-type="bibr" rid="bibr14-2047487312445001">14</xref>,<xref ref-type="bibr" rid="bibr15-2047487312445001">15</xref></sup> MPs are shed from plasma membranes via exocytosis into extracellular fluid<sup><xref ref-type="bibr" rid="bibr8-2047487312445001">8</xref>,<xref ref-type="bibr" rid="bibr16-2047487312445001">16</xref></sup> following cellular activation, injury, or apoptosis. A wide range of stimuli such as proinflammatory cytokines (e.g. tumour necrosis factor-α and interleukin-1β), bacterial lipopolysaccharides, complement proteins (C5b-9), reactive oxygen species, hypoxia, plasminogen activator inhibitor, thrombin, camptothecin, C-reactive protein, and uraemic toxins have been implicated in MP formation.<sup><xref ref-type="bibr" rid="bibr3-2047487312445001">3</xref>,<xref ref-type="bibr" rid="bibr17-2047487312445001">17</xref><xref ref-type="bibr" rid="bibr18-2047487312445001"/><xref ref-type="bibr" rid="bibr19-2047487312445001"/>–<xref ref-type="bibr" rid="bibr20-2047487312445001">20</xref></sup> This makes MPs well suited as surrogate marker of endothelial dysfunction. Immunophenotyping MPs provides an avenue for classification and association of antigenic markers with specific disease populations. At present, a phenotypically uniform marker across disease indications is lacking. However, standardization in detection of MPs and their prognostic usage might prove to be useful for risk stratification and prediction of disease outcomes for various pathological conditions and in patients at risk.</p>
<p>MPs are phenotypically classified by means of their size and composition and are known to express antigens characteristic of their cells of origin,<sup><xref ref-type="bibr" rid="bibr21-2047487312445001">21</xref></sup> carrying varying payloads that may act as proxies of cell signalling (<xref ref-type="fig" rid="fig1-2047487312445001">Figure 1</xref>). Among different classes of MPs, endothelial cells (ECs) release phenotypically and quantitatively distinct endothelial microparticles (EMPs) in activation (e.g. inducible markers) and apoptosis (e.g. constitutive markers) (<xref ref-type="table" rid="table1-2047487312445001">Table 1</xref>).<sup><xref ref-type="bibr" rid="bibr22-2047487312445001">22</xref>,<xref ref-type="bibr" rid="bibr23-2047487312445001">23</xref></sup> The ratio of the expression between constitutive and inducible antigens has been shown to reflect the nature of endothelial injury. Indeed, endothelial nitric oxide synthase dysregulation has been known to participate in the production of EMPs<sup><xref ref-type="bibr" rid="bibr24-2047487312445001">24</xref></sup> underpinning the reciprocal relationship between EMPs and NO-dependent endothelial dysfunction. Nevertheless, considerable surface antigens are shared between platelet-derived MPs (PMPs) and EMPs (<xref ref-type="table" rid="table2-2047487312445001">Table 2</xref>), which suggests causal link between vascular injury and EMP requires stringent validation.
<fig id="fig1-2047487312445001" position="float"><label>Figure 1.</label><caption><p>Endothelial microparticle (EMP) formation and their multi-faceted roles. Vesiculation of EMPs is induced by stimuli such as proinflammatory cytokines (e.g. tumour necrosis factor-α (TNFα), interleukin-1β (IL-1β)), bacterial lipopolysaccharides (LPS), C5b-9, reactive oxygen species (ROS), plasminogen activator inhibitor (PAI), thrombin, camptothecin, C-reactive protein (CRP), and uraemic toxins. MPs have been reported to express antigens and receptors characteristic of their cell of origin. During activation and apoptosis, endothelial cells release phenotypically and quantitatively distinct EMPs. Besides the verification of phosphatidylserine (PS) on EMPs, CD105 (endoglin) and CD144 (vascular endothelial-cadherin) appear to be the best combination of antigens that suggests a true EMP population. In addition, CD31 (platelet endothelial cell adhesion molecule-1) and CD105 were markedly increased on EMPs produced via apoptotic stimuli, while CD54 (intercellular adhesion molecule-1), CD62E (E-selectin) and CD106 (vascular cell adhesion molecule-1) were increased on EMPs during activation. Flow cytometry and antibody capture assays (e.g. ELISA and antibody array) provide avenues to detect EMPs. In addition to harbouring anticoagulant proteins, EMPs also play a pivotal role in angiogenesis and tissue remodelling. Other functions of EMPs include mediating endothelial cell survival and conveying biologically important information to neighbouring cells.</p></caption><graphic xlink:href="10.1177_2047487312445001-fig1.tif"/>
</fig>
<table-wrap id="table1-2047487312445001" position="float"><label>Table 1.</label><caption><p>Phenotypes of endothelial microparticles. Some studies have indicated that MPs produced via activating stimuli adopt different phenotypes from those produced via apoptosis. CD31 (PECAM-1), CD105 (endoglin), and CD144 (VE-cadherin) were found to be markedly increased on EMPs produced via apoptotic stimuli. On the other hand, CD54 (ICAM-1), CD62E (E-selectin), and CD106 (VCAM-1) increased significantly on EMPs during activation. As a result, the analysis of EMP phenotypic profiles may provide clinically useful information on the nature of endothelial injury. Importantly, the ratio of CD62E<sup>+</sup>/CD31<sup>+</sup> EMP populations, rather than their absolute numbers, has also been described as a benchmark to distinguish activation from apoptosis</p></caption>
<graphic alternate-form-of="table1-2047487312445001" xlink:href="10.1177_2047487312445001-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>CD marker</th>
<th>Antigen</th>
<th>Expression</th>
<th>References</th>
</tr></thead>
<tbody align="left">
<tr>
<td>CD31</td>
<td>PECAM-1</td>
<td>Apoptosis</td>
<td>23, 27, 38</td>
</tr>
<tr>
<td>CD54</td>
<td>ICAM-1</td>
<td>Activation</td>
<td>23, 38</td>
</tr>
<tr>
<td>CD62E</td>
<td>E-selectin</td>
<td>Activation</td>
<td>23, 27, 38</td>
</tr>
<tr>
<td>CD105</td>
<td>Endoglin</td>
<td>Apoptosis</td>
<td>23, 27, 38</td>
</tr>
<tr>
<td>CD106</td>
<td>VCAM-1</td>
<td>Activation</td>
<td>23, 27, 38</td>
</tr>
<tr>
<td>CD144</td>
<td>VE-cadherin</td>
<td>Apoptosis</td>
<td>27</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-2047487312445001"><p>CD, cluster of differentiation; EMPs, endothelial microparticles; E-selectin, endothelial-selectin; ICAM-1, intercellular adhesion molecule-1; PECAM-1, platelet endothelial cell adhesion molecule-1; VCAM-1, vascular cell adhesion molecule-1; VE-cadherin, vascular endothelial-cadherin.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table2-2047487312445001" position="float"><label>Table 2.</label><caption><p>Summary of antigens used to distinguish endothelial microparticles from platelet-derived microparticles. Antigens used to distinguish EMPs from PMPs are summarized in <xref ref-type="table" rid="table2-2047487312445001">Table 2</xref>. Although there is a lack of consensus as to which PMP marker to use in order to minimize PMP contamination, CD41a or CD42b should be included due to their platelet specificity. Some investigators such as Dey-Hazra et al.<sup><xref ref-type="bibr" rid="bibr45-2047487312445001">45</xref></sup> used CD31<sup>+</sup>/CD42<sup>−</sup> to define EMP and CD31<sup>+</sup>/CD42a<sup>+</sup> to define PMP. Others such as van Ierssel et al.<sup><xref ref-type="bibr" rid="bibr38-2047487312445001">38</xref></sup> chose to define EMPs as CD31<sup>+</sup>/CD42b<sup>−</sup>. While CD51 is exposed only on a minor subpopulation of EMPs, PMPs do not express CD51 at all. As mentioned in <xref ref-type="table" rid="table1-2047487312445001">Table 1</xref>, apoptosis-derived EMPs expressed CD31, CD105 and CD144, whereas activation-induced EMPs expressed CD54, CD62E, and CD106. CD146 has been reported as EMP specific as well. Both CD61 and CD62P can be found on endothelial cells. Despite this, some investigators have reported that CD61 and CD62P are absent on EMP thereby making them suitable for use to distinguish EMPs from PMPs</p></caption>
<graphic alternate-form-of="table2-2047487312445001" xlink:href="10.1177_2047487312445001-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>CD marker</th>
<th>Antigen</th>
<th>References</th>
</tr></thead>
<tbody align="left">
<tr>
<td>EMP</td>
<td>CD31</td>
<td>PECAM-1</td>
<td>23, 27</td>
</tr>
<tr>
<td>CD51</td>
<td>Integrin α<sub>v</sub></td>
<td>89</td>
</tr>
<tr>
<td>CD54</td>
<td>ICAM-1</td>
<td>23, 38</td>
</tr>
<tr>
<td>CD62E</td>
<td>E-selectin</td>
<td>23, 27, 38</td>
</tr>
<tr>
<td>CD105</td>
<td>Endoglin</td>
<td>23, 27, 38</td>
</tr>
<tr>
<td>CD106</td>
<td>VCAM-1</td>
<td>23, 27, 38</td>
</tr>
<tr>
<td>CD144</td>
<td>VE-cadherin</td>
<td>27</td>
</tr>
<tr>
<td>CD146</td>
<td>MelCAM</td>
<td>29, 115</td>
</tr>
<tr>
<td>PMP</td>
<td>CD31</td>
<td>PECAM-1</td>
<td>45</td>
</tr>
<tr>
<td>CD41</td>
<td>GPIIbIIIa</td>
<td>30, 50</td>
</tr>
<tr>
<td>CD42</td>
<td>GPIbIX</td>
<td>63</td>
</tr>
<tr>
<td>CD42a</td>
<td>GPIX</td>
<td>45</td>
</tr>
<tr>
<td>CD42b</td>
<td>GPIb</td>
<td>22, 30, 38</td>
</tr>
<tr>
<td>CD61</td>
<td>GPIIIa</td>
<td>30</td>
</tr>
<tr>
<td>CD62P</td>
<td>P-selectin</td>
<td>16, 72</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-2047487312445001"><p>CD, cluster of differentiation; EMP, endothelial microparticle; E-selectin, endothelial-selectin; GPIb, glycoprotein Ib; GPIbIX, glycoprotein IbIX; GPIIbIIIa, glycoprotein IIbIIIa; GPIIIa, glycoprotein IIIa; GPIX, glycoprotein IX; ICAM-1, intercellular adhesion molecule-1; MelCAM, melanoma cell adhesion molecule; PECAM-1, platelet endothelial cell adhesion molecule-1; PMP, platelet-derived microparticle; P-selectin, platelet-selectin; VCAM-1, vascular cell adhesion molecule-1; VE-cadherin, vascular endothelial-cadherin.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Circulating EMPs are known to associate with increased atherothrombotic risk in asymptomatic individuals and thus may provide potential predictive value (<xref ref-type="table" rid="table3-2047487312445001">Table 3</xref>). Nozaki and colleagues reported that plasma CD144<sup>+</sup> EMP levels could be used to predict future cardiovascular events in patients with heart failure (HF).<sup><xref ref-type="bibr" rid="bibr25-2047487312445001">25</xref></sup> In addition, plasma EMP levels could independently predict future cardiovascular events when incorporated in a multiple biomarkers strategy involving B-type natriuretic peptide and high-sensitivity C-reactive protein.<sup><xref ref-type="bibr" rid="bibr26-2047487312445001">26</xref></sup> However, disease-associated fluctuation of EMPs which are deemed useful for risk stratification and disease prognostication still awaits robust clinical validation. We review the role of EMPs in endothelial dysfunction and their multi-faceted role in vascular biology. We discuss the technical challenges in their clinical translation and the emerging role of EMPs as biomarkers in risk stratification in cardiovascular medicine.
<table-wrap id="table3-2047487312445001" position="float"><label>Table 3.</label><caption><p>Endothelial microparticles in cardiovascular diseases. EMP levels vary considerably in individuals with cardiovascular diseases (e.g. atherosclerosis, ACS, SCD, CHF, renal failure, PH, DM, stroke). In addition to facilitating risk stratification, the levels of specific EMP phenotypes can aid prognostication of diseases and their subgroups</p></caption>
<graphic alternate-form-of="table3-2047487312445001" xlink:href="10.1177_2047487312445001-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Condition</th>
<th>Specific disease state</th>
<th>EMP count</th>
<th>References</th>
</tr></thead>
<tbody align="left">
<tr>
<td align="justify">Cardiovascular risk factors</td>
<td align="justify">CAD in first degree relatives</td>
<td>Positive family history (CD31<sup>+</sup>/AnxV<sup>+</sup>: 70.37 ± 6.32/µl) Negative family history (CD31<sup>+</sup>/AnxV<sup>+</sup>: 55.31 ± 4.88/µl)</td>
<td>97</td>
</tr>
<tr>
<td align="justify">IR</td>
<td align="justify">Venous IR (CD144<sup>+</sup>: 54.3 ± 30.1/µl; CD31<sup>+</sup>/CD42<sup>−</sup>: 32.7 ± 25.6/µl)</td>
<td>108</td>
</tr>
<tr>
<td align="justify"> and IS (CD144<sup>+</sup>: 47.6 ± 25.0/µl; CD31<sup>+</sup>/CD42<sup>−</sup>: 29.1 ± 6.9/µl)</td>
</tr>
<tr>
<td align="justify">Arterial IR (CD144<sup>+</sup>: 61.0 ± 21.7/µl; CD31<sup>+</sup>/CD42<sup>−</sup>: 25.3 ± 13.7/µl)</td>
</tr>
<tr>
<td align="justify"> and IS (CD144<sup>+</sup>: 69.0 ± 48.3/µl; CD31<sup>+</sup>/CD42<sup>−</sup>: 33.7 ± 20.8/µl)</td>
</tr>
<tr>
<td align="justify">CAD</td>
<td align="justify">Atherosclerosis</td>
<td align="justify">Asymptomatic (CD144<sup>+</sup>: 9977 (0−53,271)/µg lesion)</td>
<td>72</td>
</tr>
<tr>
<td align="justify">Symptomatic (CD144<sup>+</sup>: 27105 (0−85,050)/µg lesion)</td>
</tr>
<tr>
<td align="justify">ACS (MI, UA, SA)</td>
<td align="justify">CD105<sup>+</sup> (Co: 1.48 ± 0.5 nM PS Eq vs. F: 0.77 ± 0.4 nM PS Eq)</td>
<td>93</td>
</tr>
<tr>
<td align="justify">First MI (CD31<sup>+</sup>/CD42<sup>−</sup>: 16,464/µl)</td>
<td>65</td>
</tr>
<tr>
<td align="justify">Prior MI or ACS (CD31<sup>+</sup>/CD42<sup>−</sup>: 4425/µl)</td>
</tr>
<tr>
<td align="justify">SCD</td>
<td align="justify">LV dysfunction (CD31<sup>+</sup>/AnxV<sup>+</sup>: 67.1 ± 31.6/µl)</td>
<td>94</td>
</tr>
<tr>
<td align="justify">LV preservation (CD31<sup>+</sup>/AnxV<sup>+</sup>: 32.1 ± 18.8/µl)</td>
</tr>
<tr>
<td align="justify">CHF</td>
<td align="justify">AR<sup>+</sup> (CD62E<sup>+</sup>: 78 ± 90 pM PS Eq)</td>
<td>96</td>
</tr>
<tr>
<td align="justify">AR<sup>−</sup> (CD62E<sup>+</sup>: 7 ± 26 pM PS Eq)</td>
</tr>
<tr>
<td align="justify">DM</td>
<td align="justify">Type 1/type 2</td>
<td align="justify">DM (CD144<sup>+</sup>: 0.541 (0.423 − 0.652) ×10<sup>6</sup>/ml)</td>
<td>66</td>
</tr>
<tr>
<td align="justify">DM with CAD (CD144<sup>+</sup>: 0.706 (0.577 − 1.067) ×10<sup>6</sup>/ml)</td>
</tr>
<tr>
<td align="justify">DM without MetS (CD144<sup>+</sup>: 139.07 (81.6−271.5) ×10<sup>3</sup>/ml)</td>
<td>105</td>
</tr>
<tr>
<td align="justify">DM with MetS (CD144<sup>+</sup>: 251.80 (121.2−499.3) ×10<sup>3</sup>/ml)</td>
</tr>
<tr>
<td align="justify">DM with ACS (CD144<sup>+</sup>: 442.27 (154.2−826.9) ×10<sup>3</sup>/ml)</td>
</tr>
<tr>
<td align="justify">Stroke</td>
<td align="justify">AS</td>
<td align="justify">AS Group (CD62E<sup>+</sup>: 2.01 ± 0.44/µl)</td>
<td>109</td>
</tr>
<tr>
<td align="justify">RF Group (CD62E<sup>+</sup>: 1.75 ± 0.40/µl)</td>
</tr>
<tr>
<td align="justify">ICAS Group (CD31<sup>+</sup>/CD42b<sup>−</sup>: 2.12 ± 0.52/µl; CD31<sup>+</sup>/AnxV<sup>+</sup>: 2.06 ± 0.55/µl; CD62E<sup>+</sup>: 1.67 ± 0.31)</td>
</tr>
<tr>
<td align="justify">ECAS Group (CD31<sup>+</sup>/CD42b<sup>−</sup>: 1.91 ± 0.46/ml; CD31<sup>+</sup>/AnxV<sup>+</sup>: 1.80 ± 0.51/ml; CD62E<sup>+</sup>: 2.12 ± 0.55/µl)</td>
</tr>
<tr>
<td align="justify">Hypertension</td>
<td align="justify">PH</td>
<td align="justify">PH vs. controls: CD62E<sup>+</sup> (303 ± 59 vs. 75 ± 12/µl)</td>
<td>69</td>
</tr>
<tr>
<td align="justify"> CD144<sup>+</sup> (932 ± 158 vs. 199 ± 33/µl)</td>
</tr>
<tr>
<td align="justify"> CD31<sup>+</sup>/CD41<sup>−</sup> (2357 ± 328 vs. 781 ± 132/µl)</td>
</tr>
<tr>
<td align="justify">PAH vs. CPD-PH: CD31<sup>+</sup>/CD41<sup>−</sup> and CD144<sup>+</sup> (3003 ± 432 vs. 1302 ± 254 and 1211 ± 221 vs. 458 ± 90/µl)</td>
</tr>
<tr>
<td align="justify">PH vs. controls: CD31<sup>+</sup>/CD41<sup>−</sup> (2480 ± 366/µl vs. 781 ± 132/µl)</td>
<td>111</td>
</tr>
<tr>
<td align="justify"> CD144<sup>+</sup> (1009 ± 175/µl vs. 199 ± 33/µl)</td>
</tr>
<tr>
<td align="justify"> CD62E<sup>+</sup> (328 ± 66/µl vs. 75 ± 12/µl)</td>
</tr>
<tr>
<td align="justify">CPD-PH with and without adverse events: CD62E<sup>+</sup> (765 ± 99 vs. 140 ± 50/µl)</td>
</tr>
<tr>
<td align="justify">PAH with and without adverse events: CD62E<sup>+</sup>(633 ± 133 vs. 236 ± 76/µl)</td>
</tr>
<tr>
<td align="justify">Renal failure</td>
<td align="justify">ESRF</td>
<td align="justify">Before HD vs. After HD: CD31<sup>+</sup>/CD41<sup>−</sup> (1356  ±  1066 vs. 678 ± 473/µl)</td>
<td>114</td>
</tr>
<tr>
<td align="justify">Before Hb increases vs. after Hb increases: CD31<sup>+</sup>/CD41<sup>−</sup> (1730 ± 1039 vs. 835 ± 657/µl)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-2047487312445001"><p>ACS, acute coronary syndromes; AnxV, annexin V; AR<sup>−</sup>, without acute allograft rejection; AR<sup>+</sup>, acute allograft rejection; AS, acute stroke; CAD, coronary artery disease; CD, cluster of differentiation; CHF, chronic heart failure; Co, within occluded artery; CPD-PH, chronic pulmonary disease-PH; DM, diabetes mellitus; ECAS, extracranial arterial stenosis; EMPs, endothelial microparticles; ESRF, end-stage renal failure; F, peripheral blood; Hb, haemoglobin; HD, haemodialysis; ICAS, intracranial arterial stenosis; IR, insulin resistant; IS, insulin sensitive; LV, left ventricular; MetS, metabolic syndrome; MI, myocardial infarction; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PS Eq, phospholipid equivalent; RF, risk factors; SA, stable angina; SCD, stable coronary disease; UA, unstable angina.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table4-2047487312445001" position="float"><label>Table 4.</label><caption><p>Methodology in endothelial microparticle detection and analysis. Flow cytometry can be used for size calibration by adding standard beads of known diameter. Despite this, current flow cytometers have a threshold for particle size detection whereby measurements below this level of sensitivity remain uncertain in routine practice. MPs can be enumerated using flow cytometry by the fluorescent bead count-based or flow rate-based methods. A combination of three or more antigens can also be simultaneously analysed on a single MP using antibodies conjugated to different fluorophores. This practice enables smaller subpopulations of MPs to be distinguished but may also give rise to fluorescence spectral overlap. With ELISA, this technical difficulty is overcome as only 1−2 markers can be analysed at a time. Nevertheless, this also indicates that more than one ELISA assays are required if more information is desired. Antibody microarrays, on the other hand, can contain over 80 different CD marker spots. This technology removes the need for multiple ELISA assays, thereby reducing the challenges of analysing large sample numbers and the labour demands placed by flow cytometry and ELISA techniques</p></caption><graphic alternate-form-of="table4-2047487312445001" xlink:href="10.1177_2047487312445001-table4.tif"/>
<table frame="hsides" rules="groups"><thead align="left">
<tr><th rowspan="2"/><th>Flow cytometry</th><th colspan="2">Antibody capture assays</th><th rowspan="2">References</th><th rowspan="2"/>
</tr>
<tr><th>ELISA</th><th>Microarray</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Size calibration</td>
<td>✓</td>
<td>×</td>
<td>×</td>
<td>28, 30</td>
</tr>
<tr>
<td>Detection size limit</td>
<td>✓</td>
<td>×</td>
<td>×</td>
<td>30</td>
</tr>
<tr>
<td>Enumeration</td>
<td>✓</td>
<td>×</td>
<td>×</td>
<td>28, 34−36</td>
</tr>
<tr>
<td>Multiple labelling of single microparticle</td>
<td>✓</td>
<td>×</td>
<td>×</td>
<td>12, 30</td>
</tr>
<tr>
<td>Distinguish subpopulations</td>
<td>✓</td>
<td>×</td>
<td>×</td>
<td>12, 30</td>
</tr>
<tr>
<td>Fluorescence spectral overlap</td>
<td>✓</td>
<td>×</td>
<td>×</td>
<td>12</td>
</tr>
<tr>
<td>Analysis of large sample numbers</td>
<td>×</td>
<td>×</td>
<td>✓</td>
<td>28</td>
</tr>
<tr>
<td>Labour intensive</td>
<td>✓</td>
<td>✓</td>
<td>×</td>
<td>28</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-2047487312445001"><p>CD, cluster differentiation; ELISA, enzyme-linked immunosorbent assay; MP, microparticle.</p></fn></table-wrap-foot>
</table-wrap>
</p>
</sec>
<sec id="sec2-2047487312445001"><title>Detection of microparticles</title>
<sec id="sec3-2047487312445001"><title>Flow cytometry</title>
<p>Although MPs can be detected by microscopy,<sup><xref ref-type="bibr" rid="bibr27-2047487312445001">27</xref></sup> enzyme-linked immunosorbent assays (ELISA),<sup><xref ref-type="bibr" rid="bibr28-2047487312445001">28</xref></sup> and functional assays,<sup><xref ref-type="bibr" rid="bibr28-2047487312445001">28</xref>,<xref ref-type="bibr" rid="bibr29-2047487312445001">29</xref></sup> flow cytometry is the current gold standard for MP analysis. It enables analysis of large numbers of MPs, provides information about their corpuscular characteristics and allows multiple labelling (<xref ref-type="table" rid="table4-2047487312445001">Table 4</xref>).<sup><xref ref-type="bibr" rid="bibr12-2047487312445001">12</xref>,<xref ref-type="bibr" rid="bibr30-2047487312445001">30</xref></sup> Standard beads of known diameter are used for size calibration while others employ platelets as internal standards.<sup><xref ref-type="bibr" rid="bibr31-2047487312445001">31</xref>,<xref ref-type="bibr" rid="bibr32-2047487312445001">32</xref></sup> Alternatively, some investigators regard non-MPs as particles smaller than 0.2 µm<sup><xref ref-type="bibr" rid="bibr27-2047487312445001">27</xref>,<xref ref-type="bibr" rid="bibr33-2047487312445001">33</xref></sup> or detect MPs based on fluorescent intensity.<sup><xref ref-type="bibr" rid="bibr23-2047487312445001">23</xref></sup></p>
<p>Flow cytometry has been used to enumerate MPs by adding a known count of fluorescent or non-fluorescent latex particles to the sample preceding analysis.<sup><xref ref-type="bibr" rid="bibr28-2047487312445001">28</xref>,<xref ref-type="bibr" rid="bibr34-2047487312445001">34</xref></sup> However, this method can be labour intensive and expensive depending on the number of samples analysed.<sup><xref ref-type="bibr" rid="bibr12-2047487312445001">12</xref></sup> Alternatively, when cytometer flow rate is pre-determined, sample MP count per analysed volume can be calculated. This flow rate-based method is less expensive as it uses a derived calibration factor to convert cytometer events into absolute counts.<sup><xref ref-type="bibr" rid="bibr35-2047487312445001">35</xref>,<xref ref-type="bibr" rid="bibr36-2047487312445001">36</xref></sup> Despite this, the latter can become cumbersome and impractical since recalibrations are needed when samples with different viscosities are used.</p>
<p>To reduce confounders, quantifying MPs prior to staining has been advocated. A known amount of MPs is fluorescently labelled, rather than adding antibodies to a known volume of plasma or supernatant with an unknown amount of MPs. Subsequently, mean fluorescence intensity of the analysed samples can be used to determine the total number of MPs, concentration or percentage of subpopulations of MPs and to qualitatively analyse individual differences between MP samples. This is feasible only when equal starting numbers of MPs are analysed.<sup><xref ref-type="bibr" rid="bibr12-2047487312445001">12</xref></sup> Furthermore to distinguish smaller subpopulations of MPs, simultaneous usage of three or more antibodies conjugated to different fluorophores is recommended. In fact, CD105<sup>+</sup>/CD144<sup>+</sup> may be the best combination of antigens to track a true EMP population.<sup><xref ref-type="bibr" rid="bibr30-2047487312445001">30</xref></sup> Duval A et al.<sup><xref ref-type="bibr" rid="bibr37-2047487312445001">37</xref></sup> on the other hand, proposed CD105<sup>+</sup>/CD146<sup>+</sup> as the most efficient combination to detect EMPs. Furthermore, constitutive markers such as platelet-endothelial cell adhesion molecule-1 (PECAM-1, CD31), CD105,<sup><xref ref-type="bibr" rid="bibr23-2047487312445001">23</xref>,<xref ref-type="bibr" rid="bibr27-2047487312445001">27</xref>,<xref ref-type="bibr" rid="bibr38-2047487312445001">38</xref></sup> and vascular endothelial-cadherin (VE-cadherin, CD144)<sup><xref ref-type="bibr" rid="bibr27-2047487312445001">27</xref></sup> increased markedly on EMPs in apoptosis, while inducible markers such as intercellular adhesion molecule-1 (ICAM-1, CD54), endothelial-selectin (E-selectin, CD62E), and vascular cell adhesion molecule-1 (VCAM-1, CD106) increased on EMPs only in activated endothelium.<sup><xref ref-type="bibr" rid="bibr23-2047487312445001">23</xref>,<xref ref-type="bibr" rid="bibr27-2047487312445001">27</xref>,<xref ref-type="bibr" rid="bibr38-2047487312445001">38</xref></sup> Alternatively, ratio of CD62E<sup>+</sup>/CD31<sup>+</sup> EMP populations, rather than their absolute numbers, has been described as a benchmark to distinguish cellular activation from apoptosis.<sup><xref ref-type="bibr" rid="bibr23-2047487312445001">23</xref>,<xref ref-type="bibr" rid="bibr27-2047487312445001">27</xref></sup> As a result, analysis of EMP phenotypic profiles may provide clinically useful information on the nature of endothelial injury.<sup><xref ref-type="bibr" rid="bibr23-2047487312445001">23</xref>,<xref ref-type="bibr" rid="bibr27-2047487312445001">27</xref>,<xref ref-type="bibr" rid="bibr38-2047487312445001">38</xref></sup></p>
</sec>
<sec id="sec4-2047487312445001"><title>Antibody capture assays</title>
<p>As it is impossible to detect extremely small MPs in flow cytometry, attempts have been made to measure MPs with ELISA. ELISA-based MP capture assays allow the capture of most MPs and have been designed to simplify and semi-automate MP characterization.<sup><xref ref-type="bibr" rid="bibr28-2047487312445001">28</xref></sup> Alternatively, in an antibody array format, isolated MPs were captured by antibody spots immobilized on a nitrocellulose membrane to be detected by fluorescent-labelled secondary probe.<sup><xref ref-type="bibr" rid="bibr39-2047487312445001">39</xref></sup> Analogous to ELISA-based methods, this assay lacks the size differential afforded by flow cytometry and is currently hampered by low throughput. Standardization of antibody array methods and its development may see it gain acceptance as the preferred methodology in MP research.</p>
</sec>
<sec id="sec5-2047487312445001"><title>Other assays</title>
<p>MP antigenic characteristics and membrane composition have also been examined using capillary-like electrophoresis,<sup><xref ref-type="bibr" rid="bibr40-2047487312445001">40</xref></sup> confocal microscopy,<sup><xref ref-type="bibr" rid="bibr41-2047487312445001">41</xref></sup> electron microscopy,<sup><xref ref-type="bibr" rid="bibr27-2047487312445001">27</xref>,<xref ref-type="bibr" rid="bibr42-2047487312445001">42</xref></sup> high performance liquid chromatography,<sup><xref ref-type="bibr" rid="bibr43-2047487312445001">43</xref></sup> and mass spectrometry.<sup><xref ref-type="bibr" rid="bibr44-2047487312445001">44</xref></sup> Nevertheless, assays to establish specific functions of MPs are currently under-utilized due to technical challenges involved in developing standardized and reproducible protocols.</p>
</sec>
</sec>
<sec id="sec6-2047487312445001"><title>Pre-analytical variables</title>
<sec id="sec7-2047487312445001"><title>Sample collection</title>
<p>Sample collection techniques, anticoagulant of choice, and needle bore size are some factors that can influence MP analysis. Short tourniquet application and selectively removing initial portion (about 3 ml) of blood collected with a large-bore needle have been advocated to avoid platelet/endothelial activation and contamination of blood samples by procedural related PMP or EMP release.<sup><xref ref-type="bibr" rid="bibr38-2047487312445001">38</xref>,<xref ref-type="bibr" rid="bibr45-2047487312445001">45</xref></sup> Sodium citrate is the preferred anticoagulant of choice because ethylenediaminetetraacetic acid has been reported to alter the expression of GPIIbIIIa (CD41) in platelets.<sup><xref ref-type="bibr" rid="bibr46-2047487312445001">46</xref></sup> Heparin is also a less preferred choice as it induced elevated levels of platelet- and erythrocyte-derived AnxV<sup>+</sup> MPs<sup><xref ref-type="bibr" rid="bibr47-2047487312445001">47</xref></sup> and may falsely elevate EMP counts due to the formation of EMP−platelet aggregates.<sup><xref ref-type="bibr" rid="bibr48-2047487312445001">48</xref></sup> Furthermore, blood sample processing within 1 hour of collection is essential to minimize in-vitro microvesiculation resulting from cell death.<sup><xref ref-type="bibr" rid="bibr30-2047487312445001">30</xref>,<xref ref-type="bibr" rid="bibr47-2047487312445001">47</xref></sup></p>
</sec>
<sec id="sec8-2047487312445001"><title>Centrifugation</title>
<p>Most MP isolation strategies involve an initial centrifugation step of 1500−5000 <italic>g</italic> to separate blood cells from plasma. In contrast, Shah and colleagues reported using 160 <italic>g</italic> to remove erythrocytes followed by centrifugation at 1500 <italic>g</italic> to remove contaminating platelets prior to centrifugation at 13,000 <italic>g</italic>.<sup><xref ref-type="bibr" rid="bibr47-2047487312445001">47</xref></sup> However, a study conducted by Dey-Hazara et al.<sup><xref ref-type="bibr" rid="bibr45-2047487312445001">45</xref></sup> revealed artifactual elevation of PMP counts after an initial centrifugation of samples at 1500 <italic>g</italic> compared to 5000 g even though EMP counts appear to be unaffected. Nevertheless, some reported centrifugation markedly reduced MP levels (e.g. 12,000 <italic>g</italic> for 2 min),<sup><xref ref-type="bibr" rid="bibr38-2047487312445001">38</xref></sup> others purported enhanced signal-to-noise ratio, while others cautioned that exosomes and exosome-like vesicles may be pelleted along with MPs which could contribute to erroneous results.<sup><xref ref-type="bibr" rid="bibr12-2047487312445001">12</xref>,<xref ref-type="bibr" rid="bibr28-2047487312445001">28</xref></sup> Furthermore, centrifugation under temperature control is important as heat generated is known to induce microvesiculation of cellular components in plasma.<sup><xref ref-type="bibr" rid="bibr47-2047487312445001">47</xref></sup></p>
</sec>
<sec id="sec9-2047487312445001"><title>Buffers and reagents</title>
<p>Most flow cytometers generally have a detection limit of approximately 0.5 µm.<sup><xref ref-type="bibr" rid="bibr49-2047487312445001">49</xref></sup> Limitations in instrument sensitivity render it technically challenging to discriminate MPs from cellular debris and precipitates. Orozco and Lewis<sup><xref ref-type="bibr" rid="bibr12-2047487312445001">12</xref></sup> have advocated passing 0.2 µm double-filtered phosphate-buffered saline through the machine to determine background noise of each flow cytometer to improve MP discrimination. Furthermore, all reagents were recommended to be filtered using a 0.2 µm filter to improve signal-to-noise ratio.<sup><xref ref-type="bibr" rid="bibr30-2047487312445001">30</xref>,<xref ref-type="bibr" rid="bibr45-2047487312445001">45</xref></sup></p>
</sec>
<sec id="sec10-2047487312445001"><title>Freezing and thawing</title>
<p>Most studies advocate using freshly isolated MPs immediately, but often this is logistically challenging. Platelet-free plasma (PFP) is usually stored at −80℃ and thawed once prior to testing to avoid erroneous MP readings.<sup><xref ref-type="bibr" rid="bibr46-2047487312445001">46</xref></sup> Trummer et al.<sup><xref ref-type="bibr" rid="bibr50-2047487312445001">50</xref></sup> reported reduced recovery of CD41<sup>+</sup> PMPs, but not CD62E<sup>+</sup> or CD146<sup>+</sup> EMPs post-thawed. Similar reduction of AnxV<sup>+</sup> and tissue factor positive (TF<sup>+</sup>) MPs was evident at low sample storage temperatures.<sup><xref ref-type="bibr" rid="bibr47-2047487312445001">47</xref></sup> Interestingly, it was observed that apart from CD144<sup>+</sup> EMPs, CD31<sup>+</sup>/CD42b<sup>−</sup>, CD62E<sup>+</sup>, and CD144<sup>+</sup>/CD105<sup>+</sup> EMP counts were unaffected when platelet-poor plasma was stored at 4℃ for 7 hours. In contrast, storage of platelet-poor plasma at −80℃ increased numbers of CD31<sup>+</sup>/CD42b<sup>−</sup> and CD62E<sup>+</sup> EMPs whilst reducing the numbers of CD144<sup>+</sup> EMPs.<sup><xref ref-type="bibr" rid="bibr38-2047487312445001">38</xref></sup> However, others showed no difference in MP counts between fresh samples and samples stored at −80℃. In addition, Simak et al.<sup><xref ref-type="bibr" rid="bibr51-2047487312445001">51</xref></sup> reported no differences in MP levels from samples analyzed immediately compared to freeze-thawed samples.</p>
</sec>
</sec>
<sec id="sec11-2047487312445001"><title>Endothelial microparticles as primary and secondary messengers</title>
<p>Beyond being conceived as passive vesicles released secondary to disease manifestation, EMPs are increasingly recognized to convey active physiological functions. However, it is currently unclear if EMPs exert effects on their target cells by a paracrine pathway or cell-to-MP contact. Some studies indicated that MPs operate by transferring proteins to the EC surface,<sup><xref ref-type="bibr" rid="bibr52-2047487312445001">52</xref>,<xref ref-type="bibr" rid="bibr53-2047487312445001">53</xref></sup> while others suggested mechanisms similar to phagocytosis, involving either scavenger receptors or PS receptor.<sup><xref ref-type="bibr" rid="bibr54-2047487312445001">54</xref></sup> In addition, membrane fusion between MPs and target cells may also trigger cellular activation.<sup><xref ref-type="bibr" rid="bibr55-2047487312445001">55</xref></sup></p>
<sec id="sec12-2047487312445001"><title>Proinflammatory response</title>
<p>In the peripheral circulation, PMPs form the bulk of MPs while the remaining MPs originate from leucocytes, erythrocytes, and ECs.<sup><xref ref-type="bibr" rid="bibr56-2047487312445001">56</xref></sup> MPs promote endothelial dysfunction by impairing the endothelial NO pathway and inducing proinflammatory responses.<sup><xref ref-type="bibr" rid="bibr57-2047487312445001">57</xref><xref ref-type="bibr" rid="bibr58-2047487312445001"/><xref ref-type="bibr" rid="bibr59-2047487312445001"/><xref ref-type="bibr" rid="bibr60-2047487312445001"/>–<xref ref-type="bibr" rid="bibr61-2047487312445001">61</xref></sup> Though EMPs represent a minor population of MPs, they are known to function as conveyors of biologically important information to the surrounding milieu. Experiments in cultured ECs have indicated that EMP vesiculation correlated with interleukin-6 release. This implies a close relationship between endothelial vesiculation and classical inflammatory pathways. Additionally, interaction between EMPs and naïve ECs triggers proinflammatory responses by upregulation of ICAM, messenger RNA (mRNA) expression, and soluble ICAM shedding from target cells. This paracrine effect of MPs was influenced by conditions of EMP generation because it could not be observed using EMPs from unstimulated ECs.<sup><xref ref-type="bibr" rid="bibr62-2047487312445001">62</xref></sup> Hence, indicating EMPs both as a cause and a consequence of the inflammatory response.</p>
<p>EMPs have been reported to mediate EC survival by carrying anti-coagulant proteins such as endothelial protein C receptor and activated protein C.<sup><xref ref-type="bibr" rid="bibr41-2047487312445001">41</xref></sup> Numerous clinical studies have associated EMPs with pathological conditions or patient populations with predisposing risk factors. Increased numbers of EMPs have been reported in CAD,<sup><xref ref-type="bibr" rid="bibr63-2047487312445001">63</xref></sup> atherosclerosis,<sup><xref ref-type="bibr" rid="bibr64-2047487312445001">64</xref></sup> acute MI,<sup><xref ref-type="bibr" rid="bibr65-2047487312445001">65</xref></sup> DM,<sup><xref ref-type="bibr" rid="bibr66-2047487312445001">66</xref></sup> systemic lupus erythematosus,<sup><xref ref-type="bibr" rid="bibr18-2047487312445001">18</xref></sup> metabolic syndrome (MetS),<sup><xref ref-type="bibr" rid="bibr67-2047487312445001">67</xref></sup> sickle cell disease,<sup><xref ref-type="bibr" rid="bibr68-2047487312445001">68</xref></sup> pulmonary hypertension (PH),<sup><xref ref-type="bibr" rid="bibr69-2047487312445001">69</xref></sup> and renal disease.<sup><xref ref-type="bibr" rid="bibr70-2047487312445001">70</xref></sup> However, our knowledge of EMPs in the development of clinical disorders is unclear and the link of causal or effect relationship of EMP release to a particular disease process is still being unravelled.<sup><xref ref-type="bibr" rid="bibr71-2047487312445001">71</xref></sup></p>
</sec>
<sec id="sec13-2047487312445001"><title>Prothrombotic response</title>
<p>Ability of EMPs to mediate thrombin generation was first demonstrated by reduction of clotting time of normal plasma incubated with increasing amounts of EMPs.<sup><xref ref-type="bibr" rid="bibr18-2047487312445001">18</xref></sup> This was further confirmed by demonstration that EMPs from activated cells triggered TF-dependent thrombin formation <italic>in vitro</italic> and thrombus formation <italic>in vivo</italic>.<sup><xref ref-type="bibr" rid="bibr17-2047487312445001">17</xref></sup> Procoagulant EMPs have also been found in atherosclerotic plaques<sup><xref ref-type="bibr" rid="bibr72-2047487312445001">72</xref>,<xref ref-type="bibr" rid="bibr73-2047487312445001">73</xref></sup> and in patients with ACS.<sup><xref ref-type="bibr" rid="bibr29-2047487312445001">29</xref></sup> Due to expression of endothelial adhesive molecules, TF<sup>+</sup> EMPs can bind to other cell types, such as monocytes and transfer-bioactive TF <italic>in vitro</italic>, hence amplifying the proinflammatory and procoagulant responses.<sup><xref ref-type="bibr" rid="bibr74-2047487312445001">74</xref></sup> A possible TF transfer from TF-bearing EMPs to activated platelets could also be involved in this prothrombotic response.<sup><xref ref-type="bibr" rid="bibr75-2047487312445001">75</xref></sup> Therefore, EMPs can potentially behave as biological vectors in the dissemination of procoagulant potential. Furthermore, remodelling of membrane lipids exposes PS to the outer membrane of MPs.<sup><xref ref-type="bibr" rid="bibr76-2047487312445001">76</xref>,<xref ref-type="bibr" rid="bibr77-2047487312445001">77</xref></sup> Phospholipid-rich surfaces on MPs provide a catalytic surface for the assembly of coagulation proteins (e.g. TF, factors VII, IX, X, and prothrombin) and its complexes (e.g. initiating complex, intrinsic tenase complex, and prothrombinase complex).<sup><xref ref-type="bibr" rid="bibr78-2047487312445001">78</xref></sup> The ability of MPs to initiate coagulant cascade highlights their procoagulant nature and implies that MPs may be involved in propagation of thrombosis.</p>
<p>Assessment of PS expression by means of AnxV staining was an accepted criterion for identification of ‘total MPs’.<sup><xref ref-type="bibr" rid="bibr18-2047487312445001">18</xref>,<xref ref-type="bibr" rid="bibr79-2047487312445001">79</xref></sup> However, this paradigm has been challenged as not all MPs stained positively with AnxV antibodies. Limited information is available on the non-procoagulant biological roles of AnxV<sup>−</sup> MPs. Due to these limitations, non-conventional generic dyes such as bio-maleimide may serve as alternatives for detection and quantification of MPs.<sup><xref ref-type="bibr" rid="bibr80-2047487312445001">80</xref></sup> Amongst the repertoire of cluster of differentiation (CD) markers used to detect MPs, there is an increasing interest in the role of TF-expressing MPs in thrombogenic disorders.<sup><xref ref-type="bibr" rid="bibr16-2047487312445001">16</xref>,<xref ref-type="bibr" rid="bibr74-2047487312445001">74</xref>,<xref ref-type="bibr" rid="bibr81-2047487312445001">81</xref></sup> The blebbing processes in which MPs are formed, heterogeneity of markers expressed and varying antigenic density carried by MPs renders these biological particles technically challenging to detect and analyse.</p>
</sec>
</sec>
<sec id="sec14-2047487312445001"><title>Endothelial microparticles as angiogenic and survival signals</title>
<p>EMPs have been shown to activate matrix metalloproteinase-2 and participate in remodelling of extracellular matrices.<sup><xref ref-type="bibr" rid="bibr19-2047487312445001">19</xref></sup> Membrane of EMPs may serve as a surface for plasmin generation by expressing urokinase-type plasminogen activator and its receptor, which could counteract thrombin generated by EMPs.<sup><xref ref-type="bibr" rid="bibr82-2047487312445001">82</xref></sup> By conveying plasmin, EMPs activate matrix metalloproteases which are involved in the extracellular matrix degradation and release of growth factors that play a pivotal role in tissue remodelling and angiogenesis. Consistently, EMPs derived from ischaemic muscle are known to promote endothelial proliferation and vasculogenesis.<sup><xref ref-type="bibr" rid="bibr83-2047487312445001">83</xref></sup> In contrast, EMPs were demonstrated to reduce endothelial proliferation as well as formation of new vessels <italic>in vitro</italic>.<sup><xref ref-type="bibr" rid="bibr84-2047487312445001">84</xref></sup> Similarly, high levels of EMPs isolated from human umbilical vein ECs abolished angiogenesis, although low concentration of EMPs promoted formation of capillary-like structures.<sup><xref ref-type="bibr" rid="bibr85-2047487312445001">85</xref></sup> EMPs generated and released into circulation during atherosclerosis have been shown to communicate protective activation signals to vascular cells via a horizontal transfer of mRNA. In fact, microRNA-126, which is selectively enriched in these vesicles, inhibited regulator of G-protein signalling 16, thereby unleashing C-X-C chemokine receptor type 4, resulting in increased production and release of atheroprotective C-X-C chemokine ligand 12.<sup><xref ref-type="bibr" rid="bibr55-2047487312445001">55</xref></sup> Moreover, EMP release could prevent EC apoptosis and detachment, by trapping caspase-3 in EMPs.<sup><xref ref-type="bibr" rid="bibr86-2047487312445001">86</xref></sup> Interestingly, statins were demonstrated to improve the overall condition of vascular endothelium by facilitating EMP release <italic>in vitro</italic>,<sup><xref ref-type="bibr" rid="bibr87-2047487312445001">87</xref></sup> even though the effects of statins on EMP release is still debatable.<sup><xref ref-type="bibr" rid="bibr88-2047487312445001">88</xref>,<xref ref-type="bibr" rid="bibr89-2047487312445001">89</xref></sup></p>
</sec>
<sec id="sec15-2047487312445001"><title>Endothelial microparticles as indicators for endothelial dysfunction</title>
<p>Current cardiovascular risk stratification using non-specific parameters such as Framingham score, B-type natriuretic peptide, and high-sensitivity C-reactive protein has been inadequate in predicting development of cardiovascular complications in stable patients at high risk of developing coronary heart disease.<sup><xref ref-type="bibr" rid="bibr26-2047487312445001">26</xref></sup> Enumerating and phenotypically classifying EMP subgroups reveal endothelial dysfunction in many diseases (<xref ref-type="table" rid="table5-2047487312445001">Table 5</xref>). Such EMP subclassification may permit risk assessment and provide prognostic interrogation in specific vascular beds, which has direct implications in therapeutic management of disease.
<table-wrap id="table5-2047487312445001" position="float"><label>Table 5.</label><caption><p>Endothelial microparticle phenotypes and disease association. During activation or apoptosis, EMPs may present distinctively different antigenic phenotypes, which permit identification of the nature of endothelial injury</p></caption>
<graphic alternate-form-of="table5-2047487312445001" xlink:href="10.1177_2047487312445001-table5.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Condition</th>
<th rowspan="2">Specific disease state</th>
<th align="center" colspan="12">EMP phenotypes</th>
<th rowspan="2">Major findings of Study</th>
<th rowspan="2">References</th>
</tr>
<tr><th>CD31</th>
<th>CD41</th>
<th>CD42</th>
<th>CD45</th>
<th>CD51</th>
<th>CD62E</th>
<th>CD105</th>
<th>CD144</th>
<th>CD146</th>
<th>AnxV</th>
<th>T-cad</th>
<th>MCP-1</th>
</tr></thead>
<tbody align="left">
<tr>
<td>CAD</td>
<td>Atherosclerosis</td>
<td align="center">+</td>
<td align="center">+</td>
<td align="justify">CD31<sup>+</sup>/AnxV<sup>+</sup> correlated with coronary endothelial dysfunction in CAD patients</td>
<td align="justify">90</td>
</tr>
<tr>
<td align="center">+</td>
<td align="center">+</td>
<td align="center">+</td>
<td align="center">+</td>
<td align="justify">T-cad can be used as a marker for early-stage atherosclerosis that is clinically silent</td>
<td align="justify">64</td>
</tr>
<tr>
<td align="justify">Acute</td>
<td align="center">+</td>
<td align="justify">CD31<sup>+</sup>/CD42<sup>−</sup> EMPs differentiated patients with ACS from patients with SCD and controls</td>
<td align="justify">63</td>
</tr>
<tr>
<td align="center">+</td>
<td align="center">+</td>
<td align="justify">Elevated in acute endothelial injury</td>
<td align="justify">29</td>
</tr>
<tr>
<td align="center">+</td>
<td align="justify">Elevated in angiographic lesions and correlated with coronary endothelial damage</td>
<td align="justify">93</td>
</tr>
<tr>
<td align="center">+</td>
<td align="justify">CD31<sup>+</sup>/CD42<sup>−</sup> EMP levels were higher in patients with high risk lesions (e.g. eccentric type II or thrombi present)</td>
<td align="justify">65</td>
</tr>
<tr>
<td align="justify">Stable</td>
<td align="center">+</td>
<td align="center">+</td>
<td align="justify">Higher CD31<sup>+</sup>/AnxV<sup>+</sup> EMPs were found in stable CAD patients presenting with LV dysfunction compared to those with preserved LV function</td>
<td align="justify">94</td>
</tr>
<tr>
<td align="center">+</td>
<td align="center">+</td>
<td align="center">+</td>
<td align="center">+</td>
<td align="center">+</td>
<td align="justify">CD105<sup>+</sup>/CD41a<sup>+</sup> EMP−platelet aggregates were found in stable CAD, of which CD105<sup>+</sup> elements were also CD31<sup>+</sup>, CD62E<sup>+</sup> and MCP-1<sup>+</sup></td>
<td align="justify">48</td>
</tr>
<tr>
<td align="justify">CHF</td>
<td align="center">+</td>
<td align="justify">Elevated in acute allograft rejection</td>
<td align="justify">96</td>
</tr>
<tr>
<td align="center">+</td>
<td align="center">+</td>
<td align="justify">Elevated in HF patients compared to controls and post-transplant patients</td>
<td align="justify">95</td>
</tr>
<tr>
<td align="center">+</td>
<td align="justify">Independent predictor of future cardiovascular events (e.g. cardiac death)</td>
<td align="justify">25</td>
</tr>
<tr>
<td align="justify">DM</td>
<td align="justify">Type 1</td>
<td align="center">+</td>
<td align="justify">CD51<sup>+</sup>/CD41<sup>−</sup> levels correlated with albuminuria and microvascular complications (e.g. diabetic nephropathy)</td>
<td align="justify">102</td>
</tr>
<tr>
<td align="justify">Type 2</td>
<td align="center">+</td>
<td align="justify">Identified a subpopulation of type 2 DM patients at risk of developing CAD</td>
<td align="justify">66</td>
</tr>
<tr>
<td align="center">+</td>
<td align="justify">Correlated with AUC glucose, impaired FMD, increased risk of atherogenesis and CVD</td>
<td align="justify">92</td>
</tr>
<tr>
<td align="center">+</td>
<td align="center">+</td>
<td align="justify">CD31<sup>+</sup>/CD42<sup>−</sup> and CD51<sup>+</sup> EMP levels negatively correlated with FMD and positively correlated with baPWV in type 2 DM patients</td>
<td align="justify">103</td>
</tr>
<tr>
<td align="center">+</td>
<td align="justify">CD144<sup>+</sup> EMPs were associated with coronary non-calcified plaques in type 2 DM patients with intermediate cardiovascular risk</td>
<td align="justify">105</td>
</tr>
<tr>
<td align="center">+</td>
<td align="center">+</td>
<td align="justify">Independently associated with macroangiopathy</td>
<td align="justify">104</td>
</tr>
<tr>
<td align="justify">MetS</td>
<td align="center">+</td>
<td align="justify">Associated with the development of MetS</td>
<td align="justify">107</td>
</tr>
<tr>
<td align="center">+</td>
<td align="justify">Associated with oxidative stress, MetS and negatively correlated with HDLC levels</td>
<td align="justify">67</td>
</tr>
<tr>
<td align="justify">Stroke</td>
<td align="justify">AIS</td>
<td align="center">+</td>
<td align="justify">Increased CD62E<sup>+</sup> levels associated with recurrent ischaemic episodes and infarct volume</td>
<td align="justify">109</td>
</tr>
<tr>
<td align="center">+</td>
<td align="justify">CD105<sup>+</sup>/CD41a<sup>−</sup>/CD45<sup>−</sup> correlated with brain lesion volume</td>
<td align="justify">110</td>
</tr>
<tr>
<td align="justify">Hypertension</td>
<td align="justify">PH</td>
<td align="center">+</td>
<td align="center">+</td>
<td align="justify">CD31<sup>+</sup>/CD41<sup>−</sup> and CD144<sup>+</sup> but not CD62E<sup>+</sup> EMPs predicted haemodynamic severity in PH patients.</td>
<td align="justify">69</td>
</tr>
<tr>
<td align="center">+</td>
<td align="justify">Elevated levels associated with increased risk of death and re-admission for RHF</td>
<td align="justify">111</td>
</tr>
<tr>
<td align="justify">Renal failure</td>
<td align="justify">ESRF</td>
<td align="center">+</td>
<td align="center">+</td>
<td align="justify">Elevated levels of CD31<sup>+</sup>/CD41<sup>−</sup> and CD144<sup>+</sup> EMP highly correlated with loss of FMD and indices reflecting arterial stiffness</td>
<td align="justify">113</td>
</tr>
<tr>
<td align="center">+</td>
<td align="center">+</td>
<td>Inversely correlated with SS and apoptosis</td>
<td>114</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-2047487312445001"><p>ACS, acute coronary syndromes; AIS, acute ischaemic stroke; AnxV, annexin V; AUC, area under curve; baPWV, brachial ankle pulse wave velocity; CAD, coronary artery disease; CD, cluster of differentiation; CHF, chronic heart failure; CVD, cardiovascular disease; DM, diabetes mellitus; EMP, endothelial microparticle; ESRF, end-stage renal failure; FMD, flow-mediated dilatation; HDLC, high-density lipoprotein cholesterol; HF, heart failure; LV, left ventricular; MCP-1, macrophage chemotactic protein-1; MetS, metabolic syndrome; PH, pulmonary hypertension; RHF, right heart failure; SCD, stable coronary disease; SS, shear stress; T-cad, T-cadherin.</p></fn></table-wrap-foot>
</table-wrap></p>
<sec id="sec16-2047487312445001"><title>Atherosclerosis</title>
<p>Elevated EMP levels have been reported in atherosclerotic patients.<sup><xref ref-type="bibr" rid="bibr64-2047487312445001">64</xref>,<xref ref-type="bibr" rid="bibr72-2047487312445001">72</xref>,<xref ref-type="bibr" rid="bibr90-2047487312445001">90</xref></sup> Intra-plaque EMP levels were shown to be higher than those in plasma, although there were no differences in EMP levels between symptomatic patients with stroke and transient ischaemic attacks and asymptomatic patients.<sup><xref ref-type="bibr" rid="bibr72-2047487312445001">72</xref></sup> Werner and colleagues<sup><xref ref-type="bibr" rid="bibr90-2047487312445001">90</xref></sup> reported that increased plasma levels of circulating CD31<sup>+</sup>/AnxV<sup>+</sup> apoptotic EMPs positively correlated with impairment of coronary endothelial function in CAD. This observation was independent of risk factors such as hypertension, hypercholesterolaemia, smoking, diabetes, age, or sex. Exposure to oxidative and endoplasmic reticulum (ER) stress has been shown to upregulate expression of T-cadherin (T-cad) in ECs within hours of exposure.<sup><xref ref-type="bibr" rid="bibr91-2047487312445001">91</xref></sup> In a recent study, clinical usefulness of incorporating T-cad together with classical endothelial markers was investigated in subjects with chronic CAD and non-significant atherosclerosis.<sup><xref ref-type="bibr" rid="bibr64-2047487312445001">64</xref></sup> CD31<sup>+</sup>/AnxV<sup>+</sup>/T-cad<sup>+</sup> and CD144<sup>+</sup>/T-cad<sup>+</sup> EMPs were isolated from these patients, thus indicating that these EMP phenotypes could be markers of clinically silent atherosclerosis. It was reported that higher percentages of EMPs were isolated using CD144/T-cad (25%) as opposed to that using CD31/AnxV/T-cad (18%). However, CD31 is a non-specific endothelial marker and selecting EMPs with AnxV may result in omission of AnxV<sup>−</sup> EMPs which may contain clinically useful information.</p>
</sec>
<sec id="sec17-2047487312445001"><title>Acute coronary syndromes</title>
<p>The use of CD31<sup>+</sup> as an endothelial marker is controversial as platelets also express CD31.<sup><xref ref-type="bibr" rid="bibr92-2047487312445001">92</xref></sup> To increase the efficiency of CD31 detection of EMPs, investigators have used CD31 in combination with CD42 to omit contaminating PMPs during data analysis. Interestingly, CD31<sup>+</sup>/CD42<sup>−</sup> EMP phenotype appeared to discriminate patients with ACS from patients with stable angina and healthy controls.<sup><xref ref-type="bibr" rid="bibr63-2047487312445001">63</xref></sup> In addition, CD31<sup>+</sup>/CD42<sup>−</sup> EMPs were associated more frequently with high-risk angiographic lesions.<sup><xref ref-type="bibr" rid="bibr65-2047487312445001">65</xref></sup> Higher CD31<sup>+</sup>/CD42<sup>−</sup> EMPs were also reported in patients with mild to moderate stenosis and in individuals experiencing first ACS episode. Moreover, Mallat and colleagues provided evidence of elevated CD31<sup>+</sup> and CD146<sup>+</sup> EMP phenotypes in patients with ACS compared to those with stable angina and noncoronary (NC) heart disease.<sup><xref ref-type="bibr" rid="bibr29-2047487312445001">29</xref></sup> Collectively, the CD31<sup>+</sup>/CD42<sup>−</sup> and CD146<sup>+</sup> EMP phenotypes may be important markers for identifying acute endothelial injury during acute ischaemia. In contrast, CD51<sup>+</sup> EMP phenotype failed to differentiate between subgroups of CAD patients (e.g. MI, unstable angina, and stable angina) as elevated levels were reported in both ACS and stable angina patients.<sup><xref ref-type="bibr" rid="bibr63-2047487312445001">63</xref></sup> Nevertheless, CD51<sup>+</sup> EMP phenotype has instead been proposed to be released under conditions of chronic ischaemia. In patients with ST-segment elevation MI, levels of CD105<sup>+</sup> EMP and TF<sup>+</sup> MP were significantly higher within the occluded artery than in peripheral blood (PB) samples.<sup><xref ref-type="bibr" rid="bibr93-2047487312445001">93</xref></sup> However, CD105 and TF are non-endothelial specific markers and the results of this study should be interpreted with caution as presence of contaminating monocyte-derived MPs cannot be ruled out completely.</p>
</sec>
<sec id="sec18-2047487312445001"><title>Stable coronary disease</title>
<p>Studies by Bulut et al.<sup><xref ref-type="bibr" rid="bibr94-2047487312445001">94</xref></sup> and Heloire et al.<sup><xref ref-type="bibr" rid="bibr48-2047487312445001">48</xref></sup> showed that EMP phenotypes consisting of CD31<sup>+</sup>/AnxV<sup>+</sup> and CD105<sup>+</sup>/CD41a<sup>+</sup>, respectively, were elevated in stable CAD. A 25% reduction of CD34<sup>+</sup>/vascular endothelial growth factor receptor 2<sup>+</sup> endothelial progenitor cells (EPCs) coupled with an increase by 109% of CD31<sup>+</sup>/AnxV<sup>+</sup> EMPs was reported in stable non-acute CAD patients presenting with significant left ventricular dysfunction in comparison to subjects with preserved left ventricular function.<sup><xref ref-type="bibr" rid="bibr94-2047487312445001">94</xref></sup> Nevertheless, results from this study were confounded by failure to exclude presence of platelets (e.g. CD41 or CD42). Elevated EMP levels detected in this study may have in fact arisen from contaminating PMPs. Conversely, CD105<sup>+</sup>/CD41a<sup>+</sup> EMP−platelet aggregates have been reported to distinguish stable coronary disease (SCD) from acute MI within the first hour of acute MI.<sup><xref ref-type="bibr" rid="bibr48-2047487312445001">48</xref></sup> However, 48 hours after the onset of acute MI, CD105<sup>+</sup>/CD41a<sup>+</sup> EMP−platelet levels were not different from those observed in SCD patients.</p>
</sec>
<sec id="sec19-2047487312445001"><title>Chronic heart failure</title>
<p>In chronic HF patients, CD62E<sup>+</sup> (E-selectin) EMP levels were significantly higher than controls and post-transplant patients.<sup><xref ref-type="bibr" rid="bibr95-2047487312445001">95</xref></sup> The clinical utility of CD62E in HF was further extended to a group of 64 heart transplant patients.<sup><xref ref-type="bibr" rid="bibr96-2047487312445001">96</xref></sup> High CD62E<sup>+</sup> EMP levels identified HF patients at risk of developing allograft rejection, thus indicating E-selectin as an independent risk factor for acute allograft rejection. However, this phenomenon was not observed when AnxV was included. Plasma CD144<sup>+</sup> EMPs were reported to associate with severity of HF and increased significantly with New York Heart Association functional class that may independently predict future cardiovascular complications (e.g. cardiac death) in vulnerable patients.<sup><xref ref-type="bibr" rid="bibr25-2047487312445001">25</xref></sup></p>
<p>Collectively, experimental evidence pointed to elevated EMP levels in individuals with increased cardiovascular risk factors (e.g. genetics, hypertriglyceridaemia, hypercholesterolaemia) and cardiovascular diseases such as ACS,<sup><xref ref-type="bibr" rid="bibr29-2047487312445001">29</xref>,<xref ref-type="bibr" rid="bibr63-2047487312445001">63</xref>,<xref ref-type="bibr" rid="bibr65-2047487312445001">65</xref>,<xref ref-type="bibr" rid="bibr93-2047487312445001">93</xref></sup> SCD,<sup><xref ref-type="bibr" rid="bibr48-2047487312445001">48</xref>,<xref ref-type="bibr" rid="bibr94-2047487312445001">94</xref></sup> and HF<sup><xref ref-type="bibr" rid="bibr95-2047487312445001">95</xref>,<xref ref-type="bibr" rid="bibr96-2047487312445001">96</xref></sup> patients. Importantly, even healthy adults predisposed with a family history of CAD associated with higher EMP levels when compared to individuals with a negative family history.<sup><xref ref-type="bibr" rid="bibr97-2047487312445001">97</xref></sup> Although EPCs have been implicated in vascular and cardiac regeneration,<sup><xref ref-type="bibr" rid="bibr98-2047487312445001">98</xref></sup> EMPs rather than EPCs may participate in the very early pathophysiological steps in initiating endothelial dysfunction, since circulating EPC levels were similar in individuals with or without genetic predisposition to CAD.<sup><xref ref-type="bibr" rid="bibr97-2047487312445001">97</xref></sup> A significantly higher CD31<sup>+</sup>/CD42<sup>−</sup> EMP to EPC ratio and increased arterial stiffness were also evident in hypercholesterolaemic subjects when compared to normocholesterolaemic subjects.<sup><xref ref-type="bibr" rid="bibr99-2047487312445001">99</xref></sup> Taken together, these data provide new insights into the role of EMPs in exacerbating endothelial dysfunction, a key aetiological factor linked to pathogenesis of future cardiovascular events that is currently under-appreciated.</p>
</sec>
<sec id="sec20-2047487312445001"><title>Diabetes (type 1, type 2, and metabolic syndrome)</title>
<p>Severe postprandial hypertriglyceridaemia-associated inflammatory response is known to associate with enhanced production of MPs.<sup><xref ref-type="bibr" rid="bibr100-2047487312445001">100</xref></sup> Indeed, Tushuizhen and colleagues<sup><xref ref-type="bibr" rid="bibr101-2047487312445001">101</xref></sup> reported mild elevations of plasma glucose and triacylglycerol, paralleled by impaired flow-mediated dilatation, increased oxidative stress and circulating levels of MPs following high-fat meals in healthy adults. The CD31<sup>+</sup>/CD41a<sup>−</sup>, CD105<sup>+</sup>, CD106<sup>+</sup> EMPs have been reported to independently predict the presence of DM.<sup><xref ref-type="bibr" rid="bibr27-2047487312445001">27</xref></sup> In addition, Sabatier et al.<sup><xref ref-type="bibr" rid="bibr102-2047487312445001">102</xref></sup> reported raised CD51<sup>+</sup> EMP levels in type 1, but not type 2 DM, which correlated with albuminuria. These findings thus indicated that CD51<sup>+</sup> EMPs could identify a subgroup of type 1 diabetic nephropathy patients. In contrast, CD31<sup>+</sup>/CD42<sup>−</sup> and CD51<sup>+</sup> EMP levels negatively correlated with flow-mediated dilatation and positively correlated with brachial−ankle pulse wave velocity in type 2 DM patients.<sup><xref ref-type="bibr" rid="bibr103-2047487312445001">103</xref></sup> However, the study conducted by Koga and colleagues<sup><xref ref-type="bibr" rid="bibr66-2047487312445001">66</xref></sup> demonstrated inability of CD31<sup>+</sup>/CD42b<sup>−</sup> EMP phenotype in identifying type 2 DM patients at risk for CAD. Disparate findings between the two studies pertaining to the potential usefulness of CD31<sup>+</sup>/CD42<sup>−</sup> could have arisen due to the different patient populations assessed. Unlike the study conducted by Koga et al., type 2 DM patients were not segregated into groups that were with or without evidence of angiographic evidence of CAD. It is noteworthy that although CD62E<sup>+</sup> EMP levels failed to predict presence of type 2 DM, CD62E<sup>+</sup>/CD31<sup>+</sup> ratio provided evidence of apoptotic endothelial injury. In a recent study comparing EMP levels between DM patients with angiopathies, CD31<sup>+</sup>/CD42b<sup>−</sup> and CD31<sup>+</sup>/AnxV<sup>+</sup> EMP levels were observed to be independently associated with macroangiopathy (e.g. CVD, CAD, and peripheral arterial disease) while CD62E<sup>+</sup> EMP levels did not.<sup><xref ref-type="bibr" rid="bibr104-2047487312445001">104</xref></sup> Furthermore, CD144<sup>+</sup> EMPs were associated with coronary non-calcified plaques in type 2 DM patients with intermediate cardiovascular risk and asymptomatic DM patients without MetS.<sup><xref ref-type="bibr" rid="bibr105-2047487312445001">105</xref></sup></p>
<p>Patients with MetS are associated with risk of developing type 2 DM and increased incidence of CVD.<sup><xref ref-type="bibr" rid="bibr106-2047487312445001">106</xref></sup> Although few studies have been conducted in patients with MetS, CD146<sup>+</sup> EMPs have been implicated in the development of MetS while CD144<sup>+</sup> EMPs positively associated with moderate fasting hypertriglycerolaemia and negatively correlated with high-density lipoprotein cholesterol levels<sup><xref ref-type="bibr" rid="bibr67-2047487312445001">67</xref>,<xref ref-type="bibr" rid="bibr107-2047487312445001">107</xref></sup> Collectively, elevated EMPs are known to present in diabetic patients<sup><xref ref-type="bibr" rid="bibr27-2047487312445001">27</xref>,<xref ref-type="bibr" rid="bibr66-2047487312445001">66</xref>,<xref ref-type="bibr" rid="bibr102-2047487312445001">102</xref>,<xref ref-type="bibr" rid="bibr103-2047487312445001">103</xref></sup> although similar levels of venous and arterial EMPs were observed in insulin resistance and insulin-sensitive non-diabetic subjects.<sup><xref ref-type="bibr" rid="bibr108-2047487312445001">108</xref></sup> EMP subtypes may enable pre-empted therapeutic intervention during early course of vascular complication in DM patients, possibly improving their prognostic outcomes.</p>
</sec>
<sec id="sec21-2047487312445001"><title>Stroke</title>
<p>At present, there are limited clinical studies investigating roles of EMPs in cerebrovascular diseases.<sup><xref ref-type="bibr" rid="bibr4-2047487312445001">4</xref>,<xref ref-type="bibr" rid="bibr109-2047487312445001">109</xref></sup> Williams et al.<sup><xref ref-type="bibr" rid="bibr4-2047487312445001">4</xref></sup> and Jung et al.<sup><xref ref-type="bibr" rid="bibr109-2047487312445001">109</xref></sup> used similar EMP phenotypic markers (e.g. CD31 and CD62E) to identify acute ischaemic stroke (AIS) patients. Jung et al. reported elevated EMPs in AIS patients compared to individuals with risk factors. Similarly, elevated EMPs in AIS were also shown in another study that used other endothelial markers (e.g. CD105, CD54) and more specific endothelial markers such as CD144.<sup><xref ref-type="bibr" rid="bibr110-2047487312445001">110</xref></sup></p>
<p>EMP signature phenotypes consisting of CD31<sup>+</sup>/AnxV<sup>+</sup>, CD31<sup>+</sup>/CD42b<sup>−</sup>, CD62E<sup>+</sup>, CD62E<sup>+</sup>/CD42b<sup>−</sup>, CD105<sup>+</sup>/CD41a<sup>−</sup>/CD45<sup>−</sup>, CD105<sup>+</sup>/CD144<sup>+</sup>, CD105<sup>+</sup>/PS<sup>+</sup>/CD41a<sup>−</sup>, and CD105<sup>+</sup>/CD54<sup>+</sup>/CD45<sup>−</sup> have been employed to discriminate the severity of stroke lesions, disease outcomes, and segregate stroke from stroke mimics. CD31<sup>+</sup>/AnxV<sup>+</sup>, CD31<sup>+</sup>/CD42b<sup>−</sup>, and CD62E<sup>+</sup> phenotyping of EMP subgroups revealed that increased CD62E<sup>+</sup> levels were associated with recurrent ischaemic episodes, increased National Institutes of Health Stroke Scale scores, and infarct volumes.<sup><xref ref-type="bibr" rid="bibr109-2047487312445001">109</xref></sup> Higher levels of CD62E<sup>+</sup> and a ratio of CD62E<sup>+</sup> to CD31<sup>+</sup>/CD42b<sup>−</sup> or CD31<sup>+</sup>/AnxV<sup>+</sup> were reported for patients with extracranial arterial stenosis. This ratio had the advantage of significantly discriminating extracranial from intracranial arterial stenosis. In contrast, clinical utility of CD31<sup>+</sup>/CD42b<sup>−</sup> and CD62E<sup>+</sup>/CD42b<sup>−</sup> in differentiating AIS from stroke mimics was not feasible as similar levels were documented in both patient groups.<sup><xref ref-type="bibr" rid="bibr4-2047487312445001">4</xref></sup> Furthermore, both groups showed similar CD62E<sup>+</sup>/CD31<sup>+</sup> ratios (&lt;4.0), indicating that endothelial activation rather than apoptosis could have taken place. The authors concluded that AIS superimposed on chronic illnesses, smaller infarct sizes, and possible degradation of frozen plasma during long-term storage (1.5 years) in this study may have resulted in these differing results. Various combinations of CD105<sup>+</sup> EMP phenotypes were also adopted by Simak and colleagues<sup><xref ref-type="bibr" rid="bibr110-2047487312445001">110</xref></sup> to subclass moderate-to-severe stroke subjects compared to controls. Despite the association of stroke with EMP phenotypes depicting endothelial apoptosis, the possibility of endothelial activation cannot be ruled out as CD31<sup>+</sup> and activation markers such as CD62E were not utilized. Collectively, these results reveal interplay of vascular apoptosis and endothelial activation in the development of AIS-induced EMP release in patients with poor prognosis.</p>
</sec>
<sec id="sec22-2047487312445001"><title>Pulmonary hypertension</title>
<p>Levels of CD31<sup>+</sup>/CD41<sup>−</sup> and CD144<sup>+</sup>, but not CD62E<sup>+</sup>, EMPs have been known to predict haemodynamic severity in patients with PH. Intriguingly, CD62E levels were associated with inflammation as shown by positive correlation of CD62E and high-sensitivity C-reactive protein.<sup><xref ref-type="bibr" rid="bibr69-2047487312445001">69</xref></sup> Interestingly, levels of CD62E<sup>+</sup> EMP identified pre-capillary PH patients with adverse clinical events and ratio of CD62E<sup>+</sup>/CD31<sup>+</sup> EMPs highlighted an activation rather than apoptotic phenomenon.<sup><xref ref-type="bibr" rid="bibr111-2047487312445001">111</xref></sup> In fact, release of EMPs and PMPs into circulation has been proposed to accelerate target organ injury in hypertensive patients.<sup><xref ref-type="bibr" rid="bibr112-2047487312445001">112</xref></sup> Both EMPs and PMPs were also significantly elevated in high-risk patients with severe hypertension and strongly correlated with endothelial destruction and haemodynamic severity in PH patients. Similarly, higher levels of EMPs were found in chronic pulmonary disease-related PH patients with adverse events.<sup><xref ref-type="bibr" rid="bibr111-2047487312445001">111</xref></sup> Therefore, elevated EMP levels may serve as an early prognostic marker for haemodynamic dysregulation in both cardiac and pulmonary systems.</p>
</sec>
<sec id="sec23-2047487312445001"><title>Renal failure</title>
<p>High levels of EMPs were correlated with reduced brachial artery flow-mediated dilatation and positively correlated with indices reflecting arterial stiffness in end-stage renal failure.<sup><xref ref-type="bibr" rid="bibr113-2047487312445001">113</xref></sup> Moreover, circulating EMPs exclusively correlated with endothelial dysfunction by impairing acetylcholine-induced cyclic guanosine monophosphate release <italic>in vitro</italic>. Boulanger and colleagues<sup><xref ref-type="bibr" rid="bibr114-2047487312445001">114</xref></sup> reveal enhanced production of CD144<sup>+</sup> and CD31<sup>+</sup>/CD41<sup>−</sup> EMPs in response to endothelial apoptosis triggered by low laminar stress in end-stage renal failure. Furthermore, in chronic renal failure and haemodialysed patients, circulating levels of CD144<sup>+</sup> EMP and CD146<sup>+</sup> EMP were exclusively correlated with in-vivo endothelial dysfunction. This association of uraemic toxins with enhanced liberation of EMPs in chronic renal failure provides further evidence of EMPs in the pathogenesis of endothelial dysfunction in uraemia.<sup><xref ref-type="bibr" rid="bibr115-2047487312445001">115</xref></sup> The association of EMPs with renal dysfunction is, however, relatively new compared to other disease indications and further evidence is anticipated to strengthen its value in clinical prognosis.</p>
</sec>
</sec>
<sec id="sec24-2047487312445001"><title>Current limitations of EMP analysis</title>
<p>At present, no studies on the in-vivo release time frames of EMPs are available. In addition, limited data reflecting MP clearance from the circulation have only been conducted with respect to PMPs.<sup><xref ref-type="bibr" rid="bibr116-2047487312445001">116</xref></sup> PMPs are the most abundant MP subtype, representing about 70−90% of all circulating MPs.<sup><xref ref-type="bibr" rid="bibr12-2047487312445001">12</xref>,<xref ref-type="bibr" rid="bibr56-2047487312445001">56</xref>,<xref ref-type="bibr" rid="bibr117-2047487312445001">117</xref></sup> PMPs have been characterized using markers such as CD31 (platelets and ECs), CD41 (platelets, monocytes, and megakaryocytes), CD41a (platelets and platelet precursors), CD42a (megakaryocytes and resting and activated platelets), CD42b (megakaryocytes and platelets), CD61 (platelets and ECs), and CD62P (activated platelets, megakaryocytes, and ECs).<sup><xref ref-type="bibr" rid="bibr16-2047487312445001">16</xref>,<xref ref-type="bibr" rid="bibr68-2047487312445001">68</xref>,<xref ref-type="bibr" rid="bibr78-2047487312445001">78</xref></sup> As CD31 identified PMPs and EMPs, experiments utilizing this as a single marker for detection of EMPs must be evaulated with caution. Furthermore, CD41a or CD42b should be included to rule out presence of contaminating platelets due to their platelet specificity.</p>
<p>AnxV binding of PS is widely used to identify and quantify MPs. However, not all MPs exhibit PS on their surface. Indeed, modestly but significantly increased AnxV binding sites on ECs occur only in apoptosis and are preferentially enriched on EMPs derived from apoptotic ECs.<sup><xref ref-type="bibr" rid="bibr23-2047487312445001">23</xref></sup> It would be of interest to explore whether AnxV<sup>−</sup> EMPs are liberated as a result of endothelial activation. Taken together, the heterogeneous nature of EMPs in conjunction with the inefficiency of labelling total MPs with a single marker, contributes to varying levels of EMPs reported across current clinical studies. Further standardization and additional studies are warranted to investigate the mechanisms leading to EMP clearance and downstream effects on timing of blood collection on EMP levels.</p>
</sec>
<sec id="sec25-2047487312445001" sec-type="conclusions"><title>Conclusion</title>
<p>Plasma concentrations of EMPs have been reported to fluctuate between 10<sup>3</sup> and 10<sup>5</sup> EMPs/ml and there is no clear consensus regarding acceptable physiological levels of EMPs present in peripheral blood of individuals.<sup><xref ref-type="bibr" rid="bibr18-2047487312445001">18</xref>,<xref ref-type="bibr" rid="bibr100-2047487312445001">100</xref>,<xref ref-type="bibr" rid="bibr118-2047487312445001">118</xref></sup> Collectively, it may be concluded that apoptotic mechanisms associated with EMP release are in play during the early stages of most cardiovascular diseases. In addition, it appears that activation mechanisms may participate during chronic stages of cardiovascular diseases and in patients with poorer prognosis. It is still unclear whether EMPs are a direct cause or consequence of a disease process. However, increasing notion of enhanced release of EMPs from dysfunctional endothelium coupled with observed cytoprotective effects of EMPs in preserving vascular homeostasis have piqued our appreciation of the diverse roles of these hitherto-obscured biological messengers of endothelial physiology and disease manifestations. Technical challenges concerning handling conditions and analytical procedures of MP still await standardization and consensus building from the scientific community. It is anticipated that further investigation into specific triggers of EMP release and clearance from the circulation would help bridge the gaps in our current understanding of MP biology and to translate their biological significance in disease stratification and prognostication for overall surveillance of vascular health.</p>
</sec>
</body>
<back>
<sec id="sec26-2047487312445001"><title>Funding</title>
<p>WS is funded by the National Research Foundation of Singapore (grant number NRF CRP001-068).</p>
</sec>
<sec id="sec27-2047487312445001"><title>Conflict of interest</title>
<p>The authors do not have any conflict of interests.</p>
</sec>
<ref-list><title>References</title>
<ref id="bibr1-2047487312445001"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Endemann</surname><given-names>DH</given-names></name><name><surname>Schiffrin</surname><given-names>EL</given-names></name></person-group>. <article-title>Endothelial dysfunction</article-title>. <source>J Am Soc Nephrol</source> <year>2004</year>; <volume>15</volume>: <fpage>1983</fpage>–<lpage>1992</lpage>.</citation></ref>
<ref id="bibr2-2047487312445001"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koppenol</surname><given-names>WH</given-names></name><name><surname>Moreno</surname><given-names>JJ</given-names></name><name><surname>Pryor</surname><given-names>WA</given-names></name><etal/></person-group>. <article-title>Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide</article-title>. <source>Chem Res Toxicol</source> <year>1992</year>; <volume>5</volume>: <fpage>834</fpage>–<lpage>842</lpage>.</citation></ref>
<ref id="bibr3-2047487312445001"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lekakis</surname><given-names>J</given-names></name><name><surname>Abraham</surname><given-names>P</given-names></name><name><surname>Balbarini</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2011</year>; <volume>18</volume>: <fpage>775</fpage>–<lpage>789</lpage>.</citation></ref>
<ref id="bibr4-2047487312445001"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>JB</given-names></name><name><surname>Jauch</surname><given-names>EC</given-names></name><name><surname>Lindsell</surname><given-names>CJ</given-names></name><etal/></person-group>. <article-title>Endothelial microparticle levels are similar in acute ischemic stroke and stroke mimics due to activation and not apoptosis/necrosis</article-title>. <source>Acad Emerg Med</source> <year>2007</year>; <volume>14</volume>: <fpage>685</fpage>–<lpage>690</lpage>.</citation></ref>
<ref id="bibr5-2047487312445001"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berda-Haddad</surname><given-names>Y</given-names></name><name><surname>Robert</surname><given-names>S</given-names></name><name><surname>Salers</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1 alpha</article-title>. <source>Proc Natl Acad Sci USA</source> <year>2011</year>; <volume>108</volume>: <fpage>20684</fpage>–<lpage>20689</lpage>.</citation></ref>
<ref id="bibr6-2047487312445001"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>TH</given-names></name><name><surname>D’Asti</surname><given-names>E</given-names></name><name><surname>Magnus</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Microvesicles as mediators of intercellular communication in cancer − the emerging science of cellular ‘debris’</article-title>. <source>Semin Immunopathol</source> <year>2011</year>; <volume>33</volume>: <fpage>455</fpage>–<lpage>467</lpage>.</citation></ref>
<ref id="bibr7-2047487312445001"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schiller</surname><given-names>M</given-names></name><name><surname>Bekeredjian-Ding</surname><given-names>I</given-names></name><name><surname>Heyder</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Autoantigens are translocated into small apoptotic bodies during early stages of apoptosis</article-title>. <source>Cell Death Differ</source> <year>2008</year>; <volume>15</volume>: <fpage>183</fpage>–<lpage>191</lpage>.</citation></ref>
<ref id="bibr8-2047487312445001"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dignat-George</surname><given-names>F</given-names></name><name><surname>Boulanger</surname><given-names>CM</given-names></name></person-group>. <article-title>The many faces of endothelial microparticles</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2011</year>; <volume>31</volume>: <fpage>27</fpage>–<lpage>33</lpage>.</citation></ref>
<ref id="bibr9-2047487312445001"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caby</surname><given-names>MP</given-names></name><name><surname>Lankar</surname><given-names>D</given-names></name><name><surname>Vincendeau-Scherrer</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Exosomal-like vesicles are present in human blood plasma</article-title>. <source>Int Immunol</source> <year>2005</year>; <volume>17</volume>: <fpage>879</fpage>–<lpage>887</lpage>.</citation></ref>
<ref id="bibr10-2047487312445001"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heijnen</surname><given-names>HF</given-names></name><name><surname>Schiel</surname><given-names>AE</given-names></name><name><surname>Fijnheer</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules</article-title>. <source>Blood</source> <year>1999</year>; <volume>94</volume>: <fpage>3791</fpage>–<lpage>3799</lpage>.</citation></ref>
<ref id="bibr11-2047487312445001"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mause</surname><given-names>SF</given-names></name><name><surname>Weber</surname><given-names>C</given-names></name></person-group>. <article-title>Microparticles: protagonists of a novel communication network for intercellular information exchange</article-title>. <source>Circ Res</source> <year>2010</year>; <volume>107</volume>: <fpage>1047</fpage>–<lpage>1057</lpage>.</citation></ref>
<ref id="bibr12-2047487312445001"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orozco</surname><given-names>AF</given-names></name><name><surname>Lewis</surname><given-names>DE</given-names></name></person-group>. <article-title>Flow cytometric analysis of circulating microparticles in plasma</article-title>. <source>Cytometry A</source> <year>2010</year>; <volume>77</volume>: <fpage>502</fpage>–<lpage>514</lpage>.</citation></ref>
<ref id="bibr13-2047487312445001"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Distler</surname><given-names>JH</given-names></name><name><surname>Pisetsky</surname><given-names>DS</given-names></name><name><surname>Huber</surname><given-names>LC</given-names></name><etal/></person-group>. <article-title>Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases</article-title>. <source>Arthritis Rheum</source> <year>2005</year>; <volume>52</volume>: <fpage>3337</fpage>–<lpage>3348</lpage>.</citation></ref>
<ref id="bibr14-2047487312445001"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Denzer</surname><given-names>K</given-names></name><name><surname>van Eijk</surname><given-names>M</given-names></name><name><surname>Kleijmeer</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>Follicular dendritic cells carry MHC class II-expressing microvesicles at their surface</article-title>. <source>J Immunol</source> <year>2000</year>; <volume>165</volume>: <fpage>1259</fpage>–<lpage>1265</lpage>.</citation></ref>
<ref id="bibr15-2047487312445001"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gasser</surname><given-names>O</given-names></name><name><surname>Hess</surname><given-names>C</given-names></name><name><surname>Miot</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Characterisation and properties of ectosomes released by human polymorphonuclear neutrophils</article-title>. <source>Exp Cell Res</source> <year>2003</year>; <volume>285</volume>: <fpage>243</fpage>–<lpage>257</lpage>.</citation></ref>
<ref id="bibr16-2047487312445001"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burnier</surname><given-names>L</given-names></name><name><surname>Fontana</surname><given-names>P</given-names></name><name><surname>Kwak</surname><given-names>BR</given-names></name><etal/></person-group>. <article-title>Cell-derived microparticles in haemostasis and vascular medicine</article-title>. <source>Thromb Haemost</source> <year>2009</year>; <volume>101</volume>: <fpage>439</fpage>–<lpage>451</lpage>.</citation></ref>
<ref id="bibr17-2047487312445001"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abid Hussein</surname><given-names>MN</given-names></name><name><surname>Boing</surname><given-names>AN</given-names></name><name><surname>Biro</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Phospholipid composition of in vitro endothelial microparticles and their in-vivo thrombogenic properties</article-title>. <source>Thromb Res</source> <year>2008</year>; <volume>121</volume>: <fpage>865</fpage>–<lpage>871</lpage>.</citation></ref>
<ref id="bibr18-2047487312445001"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Combes</surname><given-names>V</given-names></name><name><surname>Simon</surname><given-names>AC</given-names></name><name><surname>Grau</surname><given-names>GE</given-names></name><etal/></person-group>. <article-title>In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant</article-title>. <source>J Clin Invest</source> <year>1999</year>; <volume>104</volume>: <fpage>93</fpage>–<lpage>102</lpage>.</citation></ref>
<ref id="bibr19-2047487312445001"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lozito</surname><given-names>TP</given-names></name><name><surname>Tuan</surname><given-names>RS</given-names></name></person-group>. <article-title>Endothelial cell microparticles act as centers of matrix metalloproteinsase-2 (MMP-2) activation and vascular matrix remodeling</article-title>. <source>J Cell Physiol</source> <year>2012</year>; <volume>227</volume>: <fpage>534</fpage>–<lpage>549</lpage>.</citation></ref>
<ref id="bibr20-2047487312445001"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shet</surname><given-names>AS</given-names></name></person-group>. <article-title>Characterizing blood microparticles: technical aspects and challenges</article-title>. <source>Vasc Health Risk Manag</source> <year>2008</year>; <volume>4</volume>: <fpage>769</fpage>–<lpage>774</lpage>.</citation></ref>
<ref id="bibr21-2047487312445001"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vandendries</surname><given-names>ER</given-names></name><name><surname>Furie</surname><given-names>BC</given-names></name><name><surname>Furie</surname><given-names>B</given-names></name></person-group>. <article-title>Role of P-selectin and PSGL-1 in coagulation and thrombosis</article-title>. <source>Thromb Haemost</source> <year>2004</year>; <volume>92</volume>: <fpage>459</fpage>–<lpage>466</lpage>.</citation></ref>
<ref id="bibr22-2047487312445001"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abid Hussein</surname><given-names>MN</given-names></name><name><surname>Meesters</surname><given-names>EW</given-names></name><name><surname>Osmanovic</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Antigenic characterization of endothelial cell-derived microparticles and their detection ex vivo</article-title>. <source>J Thromb Haemost</source> <year>2003</year>; <volume>1</volume>: <fpage>2434</fpage>–<lpage>2443</lpage>.</citation></ref>
<ref id="bibr23-2047487312445001"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jimenez</surname><given-names>JJ</given-names></name><name><surname>Jy</surname><given-names>W</given-names></name><name><surname>Mauro</surname><given-names>LM</given-names></name><etal/></person-group>. <article-title>Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis</article-title>. <source>Thromb Res</source> <year>2003</year>; <volume>109</volume>: <fpage>175</fpage>–<lpage>180</lpage>.</citation></ref>
<ref id="bibr24-2047487312445001"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JM</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>JY</given-names></name><etal/></person-group>. <article-title>C-Reactive protein-induced endothelial microparticle generation in HUVECs is related to BH4-dependent NO formation</article-title>. <source>J Vasc Res</source> <year>2007</year>; <volume>44</volume>: <fpage>241</fpage>–<lpage>248</lpage>.</citation></ref>
<ref id="bibr25-2047487312445001"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nozaki</surname><given-names>T</given-names></name><name><surname>Sugiyama</surname><given-names>S</given-names></name><name><surname>Sugamura</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Prognostic value of endothelial microparticles in patients with heart failure</article-title>. <source>Eur J Heart Fail</source> <year>2010</year>; <volume>12</volume>: <fpage>1223</fpage>–<lpage>1228</lpage>.</citation></ref>
<ref id="bibr26-2047487312445001"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nozaki</surname><given-names>T</given-names></name><name><surname>Sugiyama</surname><given-names>S</given-names></name><name><surname>Koga</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease</article-title>. <source>J Am Coll Cardiol</source> <year>2009</year>; <volume>54</volume>: <fpage>601</fpage>–<lpage>608</lpage>.</citation></ref>
<ref id="bibr27-2047487312445001"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tramontano</surname><given-names>AF</given-names></name><name><surname>Lyubarova</surname><given-names>R</given-names></name><name><surname>Tsiakos</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Circulating endothelial microparticles in diabetes mellitus</article-title>. <source>Mediators Inflamm</source> <year>2010</year>. <comment>DOI: 10.1155/2010/250476</comment>.</citation></ref>
<ref id="bibr28-2047487312445001"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jy</surname><given-names>W</given-names></name><name><surname>Horstman</surname><given-names>LL</given-names></name><name><surname>Jimenez</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>Measuring circulating cell-derived microparticles</article-title>. <source>J Thromb Haemost</source> <year>2004</year>; <volume>2</volume>: <fpage>1842</fpage>–<lpage>1851</lpage>.</citation></ref>
<ref id="bibr29-2047487312445001"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mallat</surname><given-names>Z</given-names></name><name><surname>Benamer</surname><given-names>H</given-names></name><name><surname>Hugel</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes</article-title>. <source>Circulation</source> <year>2000</year>; <volume>101</volume>: <fpage>841</fpage>–<lpage>843</lpage>.</citation></ref>
<ref id="bibr30-2047487312445001"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gelderman</surname><given-names>MP</given-names></name><name><surname>Simak</surname><given-names>J</given-names></name></person-group>. <article-title>Flow cytometric analysis of cell membrane microparticles</article-title>. <source>Methods Mol Biol</source> <year>2008</year>; <volume>484</volume>: <fpage>79</fpage>–<lpage>93</lpage>.</citation></ref>
<ref id="bibr31-2047487312445001"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nieuwland</surname><given-names>R</given-names></name><name><surname>Berckmans</surname><given-names>RJ</given-names></name><name><surname>Rotteveel-Eijkman</surname><given-names>RC</given-names></name><etal/></person-group>. <article-title>Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant</article-title>. <source>Circulation</source> <year>1997</year>; <volume>96</volume>: <fpage>3534</fpage>–<lpage>3541</lpage>.</citation></ref>
<ref id="bibr32-2047487312445001"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nieuwland</surname><given-names>R</given-names></name><name><surname>Berckmans</surname><given-names>RJ</given-names></name><name><surname>McGregor</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Cellular origin and procoagulant properties of microparticles in meningococcal sepsis</article-title>. <source>Blood</source> <year>2000</year>; <volume>95</volume>: <fpage>930</fpage>–<lpage>935</lpage>.</citation></ref>
<ref id="bibr33-2047487312445001"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boulanger</surname><given-names>CM</given-names></name><name><surname>Amabile</surname><given-names>N</given-names></name><name><surname>Tedgui</surname><given-names>A</given-names></name></person-group>. <article-title>Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease</article-title>. <source>Hypertension</source> <year>2006</year>; <volume>48</volume>: <fpage>180</fpage>–<lpage>186</lpage>.</citation></ref>
<ref id="bibr34-2047487312445001"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pattanapanyasat</surname><given-names>K</given-names></name><name><surname>Noulsri</surname><given-names>E</given-names></name><name><surname>Fucharoen</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Flow cytometric quantitation of red blood cell vesicles in thalassemia</article-title>. <source>Cytometry B Clin Cytom</source> <year>2004</year>; <volume>57</volume>: <fpage>23</fpage>–<lpage>31</lpage>.</citation></ref>
<ref id="bibr35-2047487312445001"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nantakomol</surname><given-names>D</given-names></name><name><surname>Chimma</surname><given-names>P</given-names></name><name><surname>Day</surname><given-names>NP</given-names></name><etal/></person-group>. <article-title>Quantitation of cell-derived microparticles in plasma using flow rate based calibration</article-title>. <source>Southeast Asian J Trop Med Public Health</source> <year>2008</year>; <volume>39</volume>: <fpage>146</fpage>–<lpage>153</lpage>.</citation></ref>
<ref id="bibr36-2047487312445001"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nantakomol</surname><given-names>D</given-names></name><name><surname>Imwong</surname><given-names>M</given-names></name><name><surname>Soontarawirat</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>The absolute counting of red cell-derived microparticles with red cell bead by flow rate based assay</article-title>. <source>Cytometry B Clin Cytom</source> <year>2009</year>; <volume>76</volume>: <fpage>191</fpage>–<lpage>198</lpage>.</citation></ref>
<ref id="bibr37-2047487312445001"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duval</surname><given-names>A</given-names></name><name><surname>Helley</surname><given-names>D</given-names></name><name><surname>Capron</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Endothelial dysfunction in systemic lupus patients with low disease activity: evaluation by quantification and characterization of circulating endothelial microparticles, role of anti-endothelial cell antibodies</article-title>. <source>Rheumatology (Oxford)</source> <year>2010</year>; <volume>49</volume>: <fpage>1049</fpage>–<lpage>1055</lpage>.</citation></ref>
<ref id="bibr38-2047487312445001"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Ierssel</surname><given-names>SH</given-names></name><name><surname>Van Craenenbroeck</surname><given-names>EM</given-names></name><name><surname>Conraads</surname><given-names>VM</given-names></name><etal/></person-group>. <article-title>Flow cytometric detection of endothelial microparticles (EMP): effects of centrifugation and storage alter with the phenotype studied</article-title>. <source>Thromb Res</source> <year>2010</year>; <volume>125</volume>: <fpage>332</fpage>–<lpage>339</lpage>.</citation></ref>
<ref id="bibr39-2047487312445001"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lal</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Using antibody arrays to detect microparticles from acute coronary syndrome patients based on cluster of differentiation (CD) antigen expression</article-title>. <source>Mol Cell Proteomics</source> <year>2009</year>; <volume>8</volume>: <fpage>799</fpage>–<lpage>804</lpage>.</citation></ref>
<ref id="bibr40-2047487312445001"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>G</given-names></name><name><surname>Aras</surname><given-names>O</given-names></name><name><surname>Shet</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Analysis of individual platelet-derived microparticles, comparing flow cytometry and capillary electrophoresis with laser-induced fluorescence detection</article-title>. <source>Analyst</source> <year>2003</year>; <volume>128</volume>: <fpage>581</fpage>–<lpage>588</lpage>.</citation></ref>
<ref id="bibr41-2047487312445001"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perez-Casal</surname><given-names>M</given-names></name><name><surname>Downey</surname><given-names>C</given-names></name><name><surname>Fukudome</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Activated protein C induces the release of microparticle-associated endothelial protein C receptor</article-title>. <source>Blood</source> <year>2005</year>; <volume>105</volume>: <fpage>1515</fpage>–<lpage>1522</lpage>.</citation></ref>
<ref id="bibr42-2047487312445001"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>D</given-names></name><name><surname>Montezano</surname><given-names>AC</given-names></name><name><surname>Nishigaki</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Endothelial microparticle formation by angiotensin II is mediated via Ang II receptor type I/NADPH oxidase/Rho kinase pathways targeted to lipid rafts</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2011</year>; <volume>31</volume>: <fpage>1898</fpage>–<lpage>1907</lpage>.</citation></ref>
<ref id="bibr43-2047487312445001"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weerheim</surname><given-names>AM</given-names></name><name><surname>Kolb</surname><given-names>AM</given-names></name><name><surname>Sturk</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Phospholipid composition of cell-derived microparticles determined by one-dimensional high-performance thin-layer chromatography</article-title>. <source>Anal Biochem</source> <year>2002</year>; <volume>302</volume>: <fpage>191</fpage>–<lpage>198</lpage>.</citation></ref>
<ref id="bibr44-2047487312445001"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>BA</given-names></name><name><surname>Smalley</surname><given-names>DM</given-names></name><name><surname>Cho</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>The platelet microparticle proteome</article-title>. <source>J Proteome Res</source> <year>2005</year>; <volume>4</volume>: <fpage>1516</fpage>–<lpage>1521</lpage>.</citation></ref>
<ref id="bibr45-2047487312445001"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dey-Hazra</surname><given-names>E</given-names></name><name><surname>Hertel</surname><given-names>B</given-names></name><name><surname>Kirsch</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Detection of circulating microparticles by flow cytometry: influence of centrifugation, filtration of buffer, and freezing</article-title>. <source>Vasc Health Risk Manag</source> <year>2010</year>; <volume>6</volume>: <fpage>1125</fpage>–<lpage>1133</lpage>.</citation></ref>
<ref id="bibr46-2047487312445001"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piccin</surname><given-names>A</given-names></name><name><surname>Murphy</surname><given-names>WG</given-names></name><name><surname>Smith</surname><given-names>OP</given-names></name></person-group>. <article-title>Circulating microparticles: pathophysiology and clinical implications</article-title>. <source>Blood Rev</source> <year>2007</year>; <volume>21</volume>: <fpage>157</fpage>–<lpage>171</lpage>.</citation></ref>
<ref id="bibr47-2047487312445001"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>MD</given-names></name><name><surname>Bergeron</surname><given-names>AL</given-names></name><name><surname>Dong</surname><given-names>JF</given-names></name><etal/></person-group>. <article-title>Flow cytometric measurement of microparticles: pitfalls and protocol modifications</article-title>. <source>Platelets</source> <year>2008</year>; <volume>19</volume>: <fpage>365</fpage>–<lpage>372</lpage>.</citation></ref>
<ref id="bibr48-2047487312445001"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heloire</surname><given-names>F</given-names></name><name><surname>Weill</surname><given-names>B</given-names></name><name><surname>Weber</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Aggregates of endothelial microparticles and platelets circulate in peripheral blood. Variations during stable coronary disease and acute myocardial infarction</article-title>. <source>Thromb Res</source> <year>2003</year>; <volume>110</volume>: <fpage>173</fpage>–<lpage>180</lpage>.</citation></ref>
<ref id="bibr49-2047487312445001"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>S</given-names></name><name><surname>Poncelet</surname><given-names>P</given-names></name><name><surname>Lacroix</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: a first step towards multicenter studies?</article-title> <source>J Thromb Haemost</source> <year>2009</year>; <volume>7</volume>: <fpage>190</fpage>–<lpage>197</lpage>.</citation></ref>
<ref id="bibr50-2047487312445001"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trummer</surname><given-names>A</given-names></name><name><surname>De Rop</surname><given-names>C</given-names></name><name><surname>Tiede</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Recovery and composition of microparticles after snap-freezing depends on thawing temperature</article-title>. <source>Blood Coagul Fibrinolysis</source> <year>2009</year>; <volume>20</volume>: <fpage>52</fpage>–<lpage>56</lpage>.</citation></ref>
<ref id="bibr51-2047487312445001"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simak</surname><given-names>J</given-names></name><name><surname>Holada</surname><given-names>K</given-names></name><name><surname>Risitano</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria</article-title>. <source>Br J Haematol</source> <year>2004</year>; <volume>125</volume>: <fpage>804</fpage>–<lpage>813</lpage>.</citation></ref>
<ref id="bibr52-2047487312445001"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Majka</surname><given-names>M</given-names></name><name><surname>Kijowski</surname><given-names>J</given-names></name><name><surname>Lesko</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Evidence that platelet-derived microvesicles may transfer platelet-specific immunoreactive antigens to the surface of endothelial cells and CD34<sup>+</sup> hematopoietic stem/progenitor cells − implication for the pathogenesis of immune thrombocytopenias</article-title>. <source>Folia Histochem Cytobiol</source> <year>2007</year>; <volume>45</volume>: <fpage>27</fpage>–<lpage>32</lpage>.</citation></ref>
<ref id="bibr53-2047487312445001"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mause</surname><given-names>SF</given-names></name><name><surname>von Hundelshausen</surname><given-names>P</given-names></name><name><surname>Zernecke</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2005</year>; <volume>25</volume>: <fpage>1512</fpage>–<lpage>1518</lpage>.</citation></ref>
<ref id="bibr54-2047487312445001"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kirsch</surname><given-names>T</given-names></name><name><surname>Woywodt</surname><given-names>A</given-names></name><name><surname>Beese</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Engulfment of apoptotic cells by microvascular endothelial cells induces proinflammatory responses</article-title>. <source>Blood</source> <year>2007</year>; <volume>109</volume>: <fpage>2854</fpage>–<lpage>2862</lpage>.</citation></ref>
<ref id="bibr55-2047487312445001"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zernecke</surname><given-names>A</given-names></name><name><surname>Bidzhekov</surname><given-names>K</given-names></name><name><surname>Noels</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection</article-title>. <source>Sci Signal</source> <year>2009</year>; <volume>2</volume>: <fpage>ra81</fpage>–<lpage>ra81</lpage>.</citation></ref>
<ref id="bibr56-2047487312445001"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simak</surname><given-names>J</given-names></name><name><surname>Gelderman</surname><given-names>MP</given-names></name></person-group>. <article-title>Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers</article-title>. <source>Transfus Med Rev</source> <year>2006</year>; <volume>20</volume>: <fpage>1</fpage>–<lpage>26</lpage>.</citation></ref>
<ref id="bibr57-2047487312445001"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barry</surname><given-names>OP</given-names></name><name><surname>Kazanietz</surname><given-names>MG</given-names></name><name><surname>Pratico</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2-dependent prostaglandin formation via a protein kinase C/mitogen-activated protein kinase-dependent pathway</article-title>. <source>J Biol Chem</source> <year>1999</year>; <volume>274</volume>: <fpage>7545</fpage>–<lpage>7556</lpage>.</citation></ref>
<ref id="bibr58-2047487312445001"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boulanger</surname><given-names>CM</given-names></name><name><surname>Scoazec</surname><given-names>A</given-names></name><name><surname>Ebrahimian</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction</article-title>. <source>Circulation</source> <year>2001</year>; <volume>104</volume>: <fpage>2649</fpage>–<lpage>2652</lpage>.</citation></ref>
<ref id="bibr59-2047487312445001"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brodsky</surname><given-names>SV</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Nasjletti</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Endothelium-derived microparticles impair endothelial function in vitro</article-title>. <source>Am J Physiol Heart Circ Physiol</source> <year>2004</year>; <volume>286</volume>: <fpage>H1910</fpage>–<lpage>H1915</lpage>.</citation></ref>
<ref id="bibr60-2047487312445001"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Tesse</surname><given-names>A</given-names></name><name><surname>Hugel</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Shed membrane particles from T lymphocytes impair endothelial function and regulate endothelial protein expression</article-title>. <source>Circulation</source> <year>2004</year>; <volume>109</volume>: <fpage>1653</fpage>–<lpage>1659</lpage>.</citation></ref>
<ref id="bibr61-2047487312445001"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>VanWijk</surname><given-names>MJ</given-names></name><name><surname>VanBavel</surname><given-names>E</given-names></name><name><surname>Sturk</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Microparticles in cardiovascular diseases</article-title>. <source>Cardiovasc Res</source> <year>2003</year>; <volume>59</volume>: <fpage>277</fpage>–<lpage>287</lpage>.</citation></ref>
<ref id="bibr62-2047487312445001"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Curtis</surname><given-names>AM</given-names></name><name><surname>Wilkinson</surname><given-names>PF</given-names></name><name><surname>Gui</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>p38 mitogen-activated protein kinase targets the production of proinflammatory endothelial microparticles</article-title>. <source>J Thromb Haemost</source> <year>2009</year>; <volume>7</volume>: <fpage>701</fpage>–<lpage>709</lpage>.</citation></ref>
<ref id="bibr63-2047487312445001"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernal-Mizrachi</surname><given-names>L</given-names></name><name><surname>Jy</surname><given-names>W</given-names></name><name><surname>Jimenez</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>High levels of circulating endothelial microparticles in patients with acute coronary syndromes</article-title>. <source>Am Heart J</source> <year>2003</year>; <volume>145</volume>: <fpage>962</fpage>–<lpage>970</lpage>.</citation></ref>
<ref id="bibr64-2047487312445001"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Philippova</surname><given-names>M</given-names></name><name><surname>Suter</surname><given-names>Y</given-names></name><name><surname>Toggweiler</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>T-cadherin is present on endothelial microparticles and is elevated in plasma in early atherosclerosis</article-title>. <source>Eur Heart J</source> <year>2011</year>; <volume>32</volume>: <fpage>760</fpage>–<lpage>771</lpage>.</citation></ref>
<ref id="bibr65-2047487312445001"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernal-Mizrachi</surname><given-names>L</given-names></name><name><surname>Jy</surname><given-names>W</given-names></name><name><surname>Fierro</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Endothelial microparticles correlate with high-risk angiographic lesions in acute coronary syndromes</article-title>. <source>Int J Cardiol</source> <year>2004</year>; <volume>97</volume>: <fpage>439</fpage>–<lpage>446</lpage>.</citation></ref>
<ref id="bibr66-2047487312445001"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koga</surname><given-names>H</given-names></name><name><surname>Sugiyama</surname><given-names>S</given-names></name><name><surname>Kugiyama</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease</article-title>. <source>J Am Coll Cardiol</source> <year>2005</year>; <volume>45</volume>: <fpage>1622</fpage>–<lpage>1630</lpage>.</citation></ref>
<ref id="bibr67-2047487312445001"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Helal</surname><given-names>O</given-names></name><name><surname>Defoort</surname><given-names>C</given-names></name><name><surname>Robert</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Increased levels of microparticles originating from endothelial cells, platelets and erythrocytes in subjects with metabolic syndrome: relationship with oxidative stress</article-title>. <source>Nutr Metab Cardiovasc Dis</source> <year>2011</year>; <volume>21</volume>: <fpage>665</fpage>–<lpage>671</lpage>.</citation></ref>
<ref id="bibr68-2047487312445001"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shet</surname><given-names>AS</given-names></name><name><surname>Aras</surname><given-names>O</given-names></name><name><surname>Gupta</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes</article-title>. <source>Blood</source> <year>2003</year>; <volume>102</volume>: <fpage>2678</fpage>–<lpage>2683</lpage>.</citation></ref>
<ref id="bibr69-2047487312445001"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amabile</surname><given-names>N</given-names></name><name><surname>Heiss</surname><given-names>C</given-names></name><name><surname>Real</surname><given-names>WM</given-names></name><etal/></person-group>. <article-title>Circulating endothelial microparticle levels predict hemodynamic severity of pulmonary hypertension</article-title>. <source>Am J Respir Crit Care Med</source> <year>2008</year>; <volume>177</volume>: <fpage>1268</fpage>–<lpage>1275</lpage>.</citation></ref>
<ref id="bibr70-2047487312445001"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dursun</surname><given-names>I</given-names></name><name><surname>Poyrazoglu</surname><given-names>HM</given-names></name><name><surname>Gunduz</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>The relationship between circulating endothelial microparticles and arterial stiffness and atherosclerosis in children with chronic kidney disease</article-title>. <source>Nephrol Dial Transplant</source> <year>2009</year>; <volume>24</volume>: <fpage>2511</fpage>–<lpage>2518</lpage>.</citation></ref>
<ref id="bibr71-2047487312445001"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chironi</surname><given-names>GN</given-names></name><name><surname>Boulanger</surname><given-names>CM</given-names></name><name><surname>Simon</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Endothelial microparticles in diseases</article-title>. <source>Cell Tissue Res</source> <year>2009</year>; <volume>335</volume>: <fpage>143</fpage>–<lpage>151</lpage>.</citation></ref>
<ref id="bibr72-2047487312445001"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leroyer</surname><given-names>AS</given-names></name><name><surname>Isobe</surname><given-names>H</given-names></name><name><surname>Leseche</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques</article-title>. <source>J Am Coll Cardiol</source> <year>2007</year>; <volume>49</volume>: <fpage>772</fpage>–<lpage>777</lpage>.</citation></ref>
<ref id="bibr73-2047487312445001"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mallat</surname><given-names>Z</given-names></name><name><surname>Hugel</surname><given-names>B</given-names></name><name><surname>Ohan</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity</article-title>. <source>Circulation</source> <year>1999</year>; <volume>99</volume>: <fpage>348</fpage>–<lpage>353</lpage>.</citation></ref>
<ref id="bibr74-2047487312445001"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabatier</surname><given-names>F</given-names></name><name><surname>Roux</surname><given-names>V</given-names></name><name><surname>Anfosso</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity</article-title>. <source>Blood</source> <year>2002</year>; <volume>99</volume>: <fpage>3962</fpage>–<lpage>3970</lpage>.</citation></ref>
<ref id="bibr75-2047487312445001"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Del Conde</surname><given-names>I</given-names></name><name><surname>Shrimpton</surname><given-names>CN</given-names></name><name><surname>Thiagarajan</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation</article-title>. <source>Blood</source> <year>2005</year>; <volume>106</volume>: <fpage>1604</fpage>–<lpage>1611</lpage>.</citation></ref>
<ref id="bibr76-2047487312445001"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Connor</surname><given-names>J</given-names></name><name><surname>Pak</surname><given-names>CC</given-names></name><name><surname>Schroit</surname><given-names>AJ</given-names></name></person-group>. <article-title>Exposure of phosphatidylserine in the outer leaflet of human red blood cells. Relationship to cell density, cell age, and clearance by mononuclear cells</article-title>. <source>J Biol Chem</source> <year>1994</year>; <volume>269</volume>: <fpage>2399</fpage>–<lpage>2404</lpage>.</citation></ref>
<ref id="bibr77-2047487312445001"><label>77</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leroyer</surname><given-names>AS</given-names></name><name><surname>Anfosso</surname><given-names>F</given-names></name><name><surname>Lacroix</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Endothelial-derived microparticles: biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis</article-title>. <source>Thromb Haemost</source> <year>2010</year>; <volume>104</volume>: <fpage>456</fpage>–<lpage>463</lpage>.</citation></ref>
<ref id="bibr78-2047487312445001"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>AP</given-names><suffix>3rd</suffix></name><name><surname>Mackman</surname><given-names>N</given-names></name></person-group>. <article-title>Microparticles in hemostasis and thrombosis</article-title>. <source>Circ Res</source> <year>2011</year>; <volume>108</volume>: <fpage>1284</fpage>–<lpage>1297</lpage>.</citation></ref>
<ref id="bibr79-2047487312445001"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>MJ</given-names></name><name><surname>Moss</surname><given-names>SE</given-names></name></person-group>. <article-title>Annexins and disease</article-title>. <source>Biochem Biophys Res Commun</source> <year>2004</year>; <volume>322</volume>: <fpage>1166</fpage>–<lpage>1170</lpage>.</citation></ref>
<ref id="bibr80-2047487312445001"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Enjeti</surname><given-names>AK</given-names></name><name><surname>Lincz</surname><given-names>L</given-names></name><name><surname>Seldon</surname><given-names>M</given-names></name></person-group>. <article-title>Bio-maleimide as a generic stain for detection and quantitation of microparticles</article-title>. <source>Int J Lab Hematol</source> <year>2008</year>; <volume>30</volume>: <fpage>196</fpage>–<lpage>199</lpage>.</citation></ref>
<ref id="bibr81-2047487312445001"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zwicker</surname><given-names>JI</given-names></name><name><surname>Trenor</surname><given-names>CC</given-names><suffix>3rd</suffix></name><name><surname>Furie</surname><given-names>BC</given-names></name><etal/></person-group>. <article-title>Tissue factor-bearing microparticles and thrombus formation</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2011</year>; <volume>31</volume>: <fpage>728</fpage>–<lpage>733</lpage>.</citation></ref>
<ref id="bibr82-2047487312445001"><label>82</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lacroix</surname><given-names>R</given-names></name><name><surname>Sabatier</surname><given-names>F</given-names></name><name><surname>Mialhe</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro</article-title>. <source>Blood</source> <year>2007</year>; <volume>110</volume>: <fpage>2432</fpage>–<lpage>2439</lpage>.</citation></ref>
<ref id="bibr83-2047487312445001"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leroyer</surname><given-names>AS</given-names></name><name><surname>Ebrahimian</surname><given-names>TG</given-names></name><name><surname>Cochain</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Microparticles from ischemic muscle promotes postnatal vasculogenesis</article-title>. <source>Circulation</source> <year>2009</year>; <volume>119</volume>: <fpage>2808</fpage>–<lpage>2817</lpage>.</citation></ref>
<ref id="bibr84-2047487312445001"><label>84</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mezentsev</surname><given-names>A</given-names></name><name><surname>Merks</surname><given-names>RM</given-names></name><name><surname>O’Riordan</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Endothelial microparticles affect angiogenesis in vitro: role of oxidative stress</article-title>. <source>Am J Physiol Heart Circ Physiol</source> <year>2005</year>; <volume>289</volume>: <fpage>H1106</fpage>–<lpage>H1114</lpage>.</citation></ref>
<ref id="bibr85-2047487312445001"><label>85</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taraboletti</surname><given-names>G</given-names></name><name><surname>D’Ascenzo</surname><given-names>S</given-names></name><name><surname>Borsotti</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells</article-title>. <source>Am J Pathol</source> <year>2002</year>; <volume>160</volume>: <fpage>673</fpage>–<lpage>680</lpage>.</citation></ref>
<ref id="bibr86-2047487312445001"><label>86</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abid Hussein</surname><given-names>MN</given-names></name><name><surname>Boing</surname><given-names>AN</given-names></name><name><surname>Sturk</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Inhibition of microparticle release triggers endothelial cell apoptosis and detachment</article-title>. <source>Thromb Haemost</source> <year>2007</year>; <volume>98</volume>: <fpage>1096</fpage>–<lpage>1107</lpage>.</citation></ref>
<ref id="bibr87-2047487312445001"><label>87</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diamant</surname><given-names>M</given-names></name><name><surname>Tushuizen</surname><given-names>ME</given-names></name><name><surname>Abid-Hussein</surname><given-names>MN</given-names></name><etal/></person-group>. <article-title>Simvastatin-induced endothelial cell detachment and microparticle release are prenylation dependent</article-title>. <source>Thromb Haemost</source> <year>2008</year>; <volume>100</volume>: <fpage>489</fpage>–<lpage>497</lpage>.</citation></ref>
<ref id="bibr88-2047487312445001"><label>88</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nomura</surname><given-names>S</given-names></name></person-group>. <article-title>Statin and endothelial cell-derived microparticles</article-title>. <source>Thromb Haemost</source> <year>2008</year>; <volume>100</volume>: <fpage>377</fpage>–<lpage>378</lpage>.</citation></ref>
<ref id="bibr89-2047487312445001"><label>89</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tramontano</surname><given-names>AF</given-names></name><name><surname>O’Leary</surname><given-names>J</given-names></name><name><surname>Black</surname><given-names>AD</given-names></name><etal/></person-group>. <article-title>Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the Rho-kinase pathway</article-title>. <source>Biochem Biophys Res Commun</source> <year>2004</year>; <volume>320</volume>: <fpage>34</fpage>–<lpage>38</lpage>.</citation></ref>
<ref id="bibr90-2047487312445001"><label>90</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Werner</surname><given-names>N</given-names></name><name><surname>Wassmann</surname><given-names>S</given-names></name><name><surname>Ahlers</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Circulating CD31<sup>+</sup>/annexin V<sup>+</sup> apoptotic microparticles correlate with coronary endothelial function in patients with coronary artery disease</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2006</year>; <volume>26</volume>: <fpage>112</fpage>–<lpage>116</lpage>.</citation></ref>
<ref id="bibr91-2047487312445001"><label>91</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kyriakakis</surname><given-names>E</given-names></name><name><surname>Philippova</surname><given-names>M</given-names></name><name><surname>Joshi</surname><given-names>MB</given-names></name><etal/></person-group>. <article-title>T-cadherin attenuates the PERK branch of the unfolded protein response and protects vascular endothelial cells from endoplasmic reticulum stress-induced apoptosis</article-title>. <source>Cell Signal</source> <year>2010</year>; <volume>22</volume>: <fpage>1308</fpage>–<lpage>1316</lpage>.</citation></ref>
<ref id="bibr92-2047487312445001"><label>92</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tushuizen</surname><given-names>ME</given-names></name><name><surname>Nieuwland</surname><given-names>R</given-names></name><name><surname>Rustemeijer</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Elevated endothelial microparticles following consecutive meals are associated with vascular endothelial dysfunction in type 2 diabetes</article-title>. <source>Diabetes Care</source> <year>2007</year>; <volume>30</volume>: <fpage>728</fpage>–<lpage>730</lpage>.</citation></ref>
<ref id="bibr93-2047487312445001"><label>93</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morel</surname><given-names>O</given-names></name><name><surname>Pereira</surname><given-names>B</given-names></name><name><surname>Averous</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Increased levels of procoagulant tissue factor-bearing microparticles within the occluded coronary artery of patients with ST-segment elevation myocardial infarction: role of endothelial damage and leukocyte activation</article-title>. <source>Atherosclerosis</source> <year>2009</year>; <volume>204</volume>: <fpage>636</fpage>–<lpage>641</lpage>.</citation></ref>
<ref id="bibr94-2047487312445001"><label>94</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bulut</surname><given-names>D</given-names></name><name><surname>Maier</surname><given-names>K</given-names></name><name><surname>Bulut-Streich</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Circulating endothelial microparticles correlate inversely with endothelial function in patients with ischemic left ventricular dysfunction</article-title>. <source>J Card Fail</source> <year>2008</year>; <volume>14</volume>: <fpage>336</fpage>–<lpage>340</lpage>.</citation></ref>
<ref id="bibr95-2047487312445001"><label>95</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>S</given-names></name><name><surname>Chirinos</surname><given-names>J</given-names></name><name><surname>Jimenez</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Phenotypic assessment of endothelial microparticles in patients with heart failure and after heart transplantation: switch from cell activation to apoptosis</article-title>. <source>J Heart Lung Transplant</source> <year>2005</year>; <volume>24</volume>: <fpage>2184</fpage>–<lpage>2189</lpage>.</citation></ref>
<ref id="bibr96-2047487312445001"><label>96</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morel</surname><given-names>O</given-names></name><name><surname>Ohlmann</surname><given-names>P</given-names></name><name><surname>Epailly</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Endothelial cell activation contributes to the release of procoagulant microparticles during acute cardiac allograft rejection</article-title>. <source>J Heart Lung Transplant</source> <year>2008</year>; <volume>27</volume>: <fpage>38</fpage>–<lpage>45</lpage>.</citation></ref>
<ref id="bibr97-2047487312445001"><label>97</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bulut</surname><given-names>D</given-names></name><name><surname>Tuns</surname><given-names>H</given-names></name><name><surname>Mugge</surname><given-names>A</given-names></name></person-group>. <article-title>CD31<sup>+</sup>/Annexin V<sup>+</sup> microparticles in healthy offsprings of patients with coronary artery disease</article-title>. <source>Eur J Clin Invest</source> <year>2009</year>; <volume>39</volume>: <fpage>17</fpage>–<lpage>22</lpage>.</citation></ref>
<ref id="bibr98-2047487312445001"><label>98</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brixius</surname><given-names>K</given-names></name><name><surname>Funcke</surname><given-names>F</given-names></name><name><surname>Graf</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Endothelial progenitor cells: a new target for the prevention of cardiovascular diseases</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2006</year>; <volume>13</volume>: <fpage>705</fpage>–<lpage>710</lpage>.</citation></ref>
<ref id="bibr99-2047487312445001"><label>99</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pirro</surname><given-names>M</given-names></name><name><surname>Schillaci</surname><given-names>G</given-names></name><name><surname>Paltriccia</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Increased ratio of CD31<sup>+</sup>/CD42<sup>−</sup> microparticles to endothelial progenitors as a novel marker of atherosclerosis in hypercholesterolemia</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2006</year>; <volume>26</volume>: <fpage>2530</fpage>–<lpage>2535</lpage>.</citation></ref>
<ref id="bibr100-2047487312445001"><label>100</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>AC</given-names></name><name><surname>Peter</surname><given-names>AA</given-names></name><name><surname>Mendez</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>Postprandial hypertriglyceridemia increases circulating levels of endothelial cell microparticles</article-title>. <source>Circulation</source> <year>2004</year>; <volume>110</volume>: <fpage>3599</fpage>–<lpage>3603</lpage>.</citation></ref>
<ref id="bibr101-2047487312445001"><label>101</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tushuizen</surname><given-names>ME</given-names></name><name><surname>Nieuwland</surname><given-names>R</given-names></name><name><surname>Scheffer</surname><given-names>PG</given-names></name><etal/></person-group>. <article-title>Two consecutive high-fat meals affect endothelial-dependent vasodilation, oxidative stress and cellular microparticles in healthy men</article-title>. <source>J Thromb Haemost</source> <year>2006</year>; <volume>4</volume>: <fpage>1003</fpage>–<lpage>1010</lpage>.</citation></ref>
<ref id="bibr102-2047487312445001"><label>102</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabatier</surname><given-names>F</given-names></name><name><surname>Darmon</surname><given-names>P</given-names></name><name><surname>Hugel</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Type 1 and type 2 diabetic patients display different patterns of cellular microparticles</article-title>. <source>Diabetes</source> <year>2002</year>; <volume>51</volume>: <fpage>2840</fpage>–<lpage>2845</lpage>.</citation></ref>
<ref id="bibr103-2047487312445001"><label>103</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Circulating level of microparticles and their correlation with arterial elasticity and endothelium-dependent dilation in patients with type 2 diabetes mellitus</article-title>. <source>Atherosclerosis</source> <year>2010</year>; <volume>208</volume>: <fpage>264</fpage>–<lpage>269</lpage>.</citation></ref>
<ref id="bibr104-2047487312445001"><label>104</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>KH</given-names></name><name><surname>Chu</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>ST</given-names></name><etal/></person-group>. <article-title>Risk of macrovascular complications in type 2 diabetes mellitus: endothelial microparticle profiles</article-title>. <source>Cerebrovasc Dis</source> <year>2011</year>; <volume>31</volume>: <fpage>485</fpage>–<lpage>493</lpage>.</citation></ref>
<ref id="bibr105-2047487312445001"><label>105</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>S</given-names></name><name><surname>Loffroy</surname><given-names>R</given-names></name><name><surname>Serusclat</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Increased levels of endothelial microparticles CD144 (VE-Cadherin) positives in type 2 diabetic patients with coronary noncalcified plaques evaluated by multidetector computed tomography (MDCT)</article-title>. <source>Atherosclerosis</source> <year>2009</year>; <volume>203</volume>: <fpage>429</fpage>–<lpage>435</lpage>.</citation></ref>
<ref id="bibr106-2047487312445001"><label>106</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>T</given-names></name><name><surname>Osugi</surname><given-names>S</given-names></name><name><surname>Shimokata</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Metabolic syndrome and all-cause mortality, cardiac events, and cardiovascular events: a follow-up study in 25,471 young- and middle-aged Japanese men</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2011</year>; <volume>18</volume>: <fpage>574</fpage>–<lpage>580</lpage>.</citation></ref>
<ref id="bibr107-2047487312445001"><label>107</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agouni</surname><given-names>A</given-names></name><name><surname>Lagrue-Lak-Hal</surname><given-names>AH</given-names></name><name><surname>Ducluzeau</surname><given-names>PH</given-names></name><etal/></person-group>. <article-title>Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome</article-title>. <source>Am J Pathol</source> <year>2008</year>; <volume>173</volume>: <fpage>1210</fpage>–<lpage>1219</lpage>.</citation></ref>
<ref id="bibr108-2047487312445001"><label>108</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>C</given-names></name><name><surname>Shemyakin</surname><given-names>A</given-names></name><name><surname>Bohm</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Endothelial microparticles in patients with insulin resistance</article-title>. <source>Diabetes Metab</source> <year>2009</year>; <volume>35</volume>: <fpage>71</fpage>–<lpage>73</lpage>.</citation></ref>
<ref id="bibr109-2047487312445001"><label>109</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>KH</given-names></name><name><surname>Chu</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>ST</given-names></name><etal/></person-group>. <article-title>Circulating endothelial microparticles as a marker of cerebrovascular disease</article-title>. <source>Ann Neurol</source> <year>2009</year>; <volume>66</volume>: <fpage>191</fpage>–<lpage>199</lpage>.</citation></ref>
<ref id="bibr110-2047487312445001"><label>110</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simak</surname><given-names>J</given-names></name><name><surname>Gelderman</surname><given-names>MP</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Circulating endothelial microparticles in acute ischemic stroke: a link to severity, lesion volume and outcome</article-title>. <source>J Thromb Haemost</source> <year>2006</year>; <volume>4</volume>: <fpage>1296</fpage>–<lpage>1302</lpage>.</citation></ref>
<ref id="bibr111-2047487312445001"><label>111</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amabile</surname><given-names>N</given-names></name><name><surname>Heiss</surname><given-names>C</given-names></name><name><surname>Chang</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Increased CD62e(<sup>+</sup>) endothelial microparticle levels predict poor outcome in pulmonary hypertension patients</article-title>. <source>J Heart Lung Transplant</source> <year>2009</year>; <volume>28</volume>: <fpage>1081</fpage>–<lpage>1086</lpage>.</citation></ref>
<ref id="bibr112-2047487312445001"><label>112</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Preston</surname><given-names>RA</given-names></name><name><surname>Jy</surname><given-names>W</given-names></name><name><surname>Jimenez</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>Effects of severe hypertension on endothelial and platelet microparticles</article-title>. <source>Hypertension</source> <year>2003</year>; <volume>41</volume>: <fpage>211</fpage>–<lpage>217</lpage>.</citation></ref>
<ref id="bibr113-2047487312445001"><label>113</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amabile</surname><given-names>N</given-names></name><name><surname>Guerin</surname><given-names>AP</given-names></name><name><surname>Leroyer</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure</article-title>. <source>J Am Soc Nephrol</source> <year>2005</year>; <volume>16</volume>: <fpage>3381</fpage>–<lpage>3388</lpage>.</citation></ref>
<ref id="bibr114-2047487312445001"><label>114</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boulanger</surname><given-names>CM</given-names></name><name><surname>Amabile</surname><given-names>N</given-names></name><name><surname>Guerin</surname><given-names>AP</given-names></name><etal/></person-group>. <article-title>In vivo shear stress determines circulating levels of endothelial microparticles in end-stage renal disease</article-title>. <source>Hypertension</source> <year>2007</year>; <volume>49</volume>: <fpage>902</fpage>–<lpage>908</lpage>.</citation></ref>
<ref id="bibr115-2047487312445001"><label>115</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Faure</surname><given-names>V</given-names></name><name><surname>Dou</surname><given-names>L</given-names></name><name><surname>Sabatier</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Elevation of circulating endothelial microparticles in patients with chronic renal failure</article-title>. <source>J Thromb Haemost</source> <year>2006</year>; <volume>4</volume>: <fpage>566</fpage>–<lpage>573</lpage>.</citation></ref>
<ref id="bibr116-2047487312445001"><label>116</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Flaumenhaft</surname><given-names>R</given-names></name></person-group>. <article-title>Formation and fate of platelet microparticles</article-title>. <source>Blood Cells Mol Dis</source> <year>2006</year>; <volume>36</volume>: <fpage>182</fpage>–<lpage>187</lpage>.</citation></ref>
<ref id="bibr117-2047487312445001"><label>117</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horstman</surname><given-names>LL</given-names></name><name><surname>Ahn</surname><given-names>YS</given-names></name></person-group>. <article-title>Platelet microparticles: a wide-angle perspective</article-title>. <source>Crit Rev Oncol Hematol</source> <year>1999</year>; <volume>30</volume>: <fpage>111</fpage>–<lpage>142</lpage>.</citation></ref>
<ref id="bibr118-2047487312445001"><label>118</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berckmans</surname><given-names>RJ</given-names></name><name><surname>Nieuwland</surname><given-names>R</given-names></name><name><surname>Boing</surname><given-names>AN</given-names></name><etal/></person-group>. <article-title>Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation</article-title>. <source>Thromb Haemost</source> <year>2001</year>; <volume>85</volume>: <fpage>639</fpage>–<lpage>646</lpage>.</citation></ref>
</ref-list>
</back>
</article>